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ABSTRACT
CAUSAL VARIANT DISCOVERY IN FAMILIAL CONGENITAL HEART DISEASE – AN
INTEGRATIVE –OMIC APPROACH
Wendy M. Demos
Marquette University, 2012

Background:
Hypoplastic left heart syndrome (HLHS) is a congenital heart defect that leads to
neonatal death or compromised quality of life for those affected and their families. This syndrome
requires extensive medical intervention for the affected to survive. It is characterized by
significant underdevelopment or non-existence of the components of the left heart and the aorta,
including the left ventricular cavity and mass. There are many factors ranging from genetics to
environmental relationships hypothesized to lead to the development of the syndrome, including
recent studies suggesting a link between hearing impairment and congenital heart defects (CHD).
Although broadly characterized those factors remain poorly understood. The goal of this project
is to systematically utilize bioinformatics tools to determine the relationships of novel mutations
found in exome sequencing to a familial congenital heart defect.
Methods
A systematic genomic and proteomic approach involving exome sequencing, pathway
analysis, and protein modeling was implemented to examine exome sequencing data of a patient
with HLHS. Subsequent findings were examined in immediate family members and relatives to
investigate inheritance and validate the relationship of novel variants to CHD in the family.
Conclusions
A rare, novel mutation in the LAMA4 gene carried by the proband and other family
members may contribute to the development of HLHS in this family.
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CHAPTER 1. INTRODUCTION
1.1 DNA Sequencing
The ability of researchers to comprehensively examine disease etiology at the genomic
level has been revolutionized by the development of high throughput DNA sequencing
technologies such as 454 pyrosequencing (Roche Diagnostics), HighSeq (Illuminia, Inc.), SOLiD
(Applied Biosystems), and Ion semiconductor sequencing (Ion Torrent Systems Inc.) These
technologies have drastically reduced DNA sequencing time and costs by generating massive
quantities of data in a fraction of the time of traditional Sanger sequencing. Researchers and
clinicians have capitalized on these technologies to further our understanding of the human
genome and causes of disease. The field of ‘genomic medicine’, which utilizes the sequence of
an individual’s exome (coding regions of genes) has transformed the capability of modern
medicine to diagnose and prescribe personalized treatment methods.
The chain terminator method of DNA sequencing (commonly referred to as the Sanger
sequencing method) utilizes a DNA polymerase that adds nucleotides to generate a
complementary strand of DNA to a single stranded DNA template. Applied Biosystems
automated this type of DNA sequencing by creating machines that could run individual reactions
in a single column rather than four simultaneous reactions on a polyacrylamide gel. These
machines provided a visual readout of the DNA sequence called a chromatogram. At the onset of
sequence automation a run of 24 samples would yield 12,000 bases of DNA per day (Adams
2008). Currently the Applied Biosystems 3130xl can generate more than 121,600 bases per day.
(Applied Biosystems).
In comparison, pyrosequencing can yield 1,000,000,000 bases or 400,000 sequencing
reads per run (Roche Diagnostics). Pyrosequencing is based on a method that measures the
release of inorganic pyrophosphate, which is converted into visible light (Metzker 2005). A series
of dNTPs are added to the reaction and a camera records emitted light after each round. The
pattern of captured light is translated into the DNA sequence.
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Unlike Sanger sequencing, 454 sequencing avoids the labor and time extensive step of
cloning the DNA template into a vector. Roche 454 sequencing employs an emulsion PCR in
which a single molecule of DNA binds to a single magnetic bead. Many beads are processed in a
water and oil mixture which in turn isolates each bead into its own water droplet. The
amplification process runs all beads in parallel and results in about 10 million clonal copies of a
single DNA fragment, each bead holding a different fragment (Roche Diagnostics). This step
alone vastly increases the starting quantity of DNA template over traditional Sanger sequencing.
Filtering through the resulting 454 sequence data to find allelic variations that may be
related to a specific phenotype is a daunting task. The DNA Sequences returned from the exome
sequencing reaction are aligned to a reference genome. This comparison aids in finding
nucleotide differences from the patient sequence to the human genome reference sequence. These
differences are termed variant. Some variants are not tolerated and presumably cause or
contribute to the development of disease. A recent investigation of the case of a 15 month old
male with a seemingly undiagnosable severe health condition supports the relationship of
sequence variation to disease. Genomic DNA from the patient was subjected to whole exome
sequencing. The sequencing reaction returned over 16,000 variants. Due to the uncommon
presentation of symptoms and condition bioinformaticians focused on variants not found in the
general population (novel) to determine which changes in the patient DNA sequence may have
been linked to the condition under investigation. This approach ultimately led to a definitive
diagnosis the patient carries a rare mutation in an apoptotic suppressor protein (XIAP) resulting in
immunodeficiency (Worthey et. al. 2011).
Establishing prospective gene candidates and conducting the subsequent investigations is
an extremely time consuming task as a result of the number of novel variants yielded by the
sequencing method, future diagnosis, preventative measures, genetic testing, or advancements in
treatment depend on an efficient approach to determine or rule out causal or contributory genes
related to disease.

3
1.2 Congenital Heart Defects
A congenital heart defect (CHD) is described as a structural condition present at birth that
can affect the heart and the way it works. CHD can affect the interior walls and valves of the
heart and the arteries and veins that carry blood to the heart and body (Knapp et. al. 2010). There
are many types of congenital heart defects which can be asymptomatic or complex with lifethreatening symptoms (NHLBI). CHD affects 1 in 100 live births and is considered one of the
most common types of birth defects. The incidence of moderate to severe forms is approximately
1% of the newborn population (Hoffman 1995, Hoffman et. al. 2002, Sander et. al. 2006). From
1999 to 2006, there were 41,494 CHD-related deaths and 27,960 deaths resulting from CHD in
the United States (Gilboa et. al. 2010).
A sub category of CHD is critical congenital heart defect (CCHD). CCHD is a group of
ductal dependent defects that cause severe and life-threatening symptoms that require
intervention within the first year of life (Knapp et. al. 2010, Chang et. al. 2008, CDC).Failure to
intervene within the first few days of life results in a fatal outcome (Barron et. al. 2009). The
seven defects that are categorized as CCHD (Table 1) represent about 17-31% of all congenital
heart defects (Knapp et. al. 2010).
Seven Defects Categorized as CCHD
Hypoplastic left heart syndrome

Total anomalous pulmonary venous return

Pulmonary atresia (with intact septum)

Transposition of the great arteries

Tetralogy of Fallot

Tricuspid atresia

Truncus arteriosus
Table 1. Types of CCHD. The seven types of CCHD according to the CDC in the context of
newborn screening using pulse oximetry (Data retrieved from:
http://www.cdc.gov/ncbddd/pediatricgenetics/pulse.html)
1.3Hypoplastic Left Heart Syndrome
Hypoplastic left heart syndrome (HLHS) is a classification of CCHD that refers to
cardiac malformations characterized by significant underdevelopment or non-existence of the
components of the left heart and the aorta, including the left ventricular cavity and mass

4
(Tchervenkov et. al. 2006). The left heart is responsible for moving oxygenated blood to the aorta
which then carries and distributes it to the rest of the body (Fogoros 2003). Defects in this system
can be severely debilitating and / or fatal to affected individuals.
Until recently, survival of the first five years of life in a person diagnosed with HLHS
ranged between 50% and 69%. With improved diagnostics and management it is now expected
that 70% of HLHS patients will survive into adulthood (Feinstein et. al. 2012). Motor or cognitive
delays characterized by impaired social skills, hampered core communications skills, impulsive
behavior, and among other related symptoms are associated to HLHS. Patients, parents, and
clinicians affected by HLHS have participated in surveys to measure their and the affected
individual’s perceived quality of life. Findings have been inconsistent due to methodology of
studies and the stress of dealing with a chronic illness (Feinstein et. al. 2012).
HLHS is described as a genetically inherited syndrome although a definitive method of
inheritance has not yet been defined. The prevalence of HLHS is not linked to any race or gender;
however, males are twice as commonly affected as females (Stumper 2010, CDC 2007). It is
known there is an increased frequency in relatives of patients with HLHS to also be affected
(Loffredo 2000, Lewin et. al. 2004). 55% of families had more than 1 affected family member
and the recurrence rate for HLHS among siblings is 8% (Grossfeld 2007)
The etiology of HLHS has broadly been studied and the consensus is that the syndrome
has multifactorial causes (Sander et. al. 2006). Linkage analysis suggesting genetic heterogeneity,
mutations at multiple genetic loci, seasonal effects, chromosomal disorders, and environmental
conditions also have been described as potential modes of the development of HLHS (Eghtesady
et. al. 2011, Grossfeld 2007, Grossfeld 1999, McBride et. al. 2008, Aberdam et. al.2002). The
hypothesis of multiple genetic loci is further supported by the strong association of HLHS with
conditions such as Trisomy 13, Trisomy 18, Turner syndrome, and Jacobson syndrome
(Grossfeld et. al. 2009).
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1.4 Objective
At this time there is no gold standard or pipeline to manage these data and rapidly
determine specific variations in relation to the disease under investigation. The goal of this thesis
is to execute a systematic and efficient approach that incorporates genomic and proteomic
analysis to investigate genomic variants found in exome sequencing of a patient (proband) with
HLHS. This approach will incorporate the use of bioinformatic tools to: design PCR primers,
align DNA sequences, determine mutation effects, conduct pathway analysis, and construct
protein models with laboratory methods such as PCR to narrow the study set of genes and
ultimately determine the path of inheritance and potential relationship of the novel variant or
variants to CHD.
A mutation was found in the LAMA4 gene of the proband. The application of the
described process provides evidence suggesting a potential causal or contributory relationship in
regards to the development of HLHS in this family. Based on previous research that HLHS is a
mutligeneic syndrome and the family history, the relationship of LAMA4 and GJB2 will also be
investigated to determine if together they are linked to the development of HLHS in this family.
1.5 Outline of Thesis
Chapter 2 provides in depth background of the genes and proteins that were the focus of
the study. Chapter 3 covers the applied approach and methods leading to the selection candidate
genes for investigation. Chapter 4 presents the results and discussion. Chapter 5 summarizes the
thesis and suggests future work.
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CHAPTER 2. BACKGROUND
After the application of the research method, the LAMA4 gene was selected as the main
gene of interest to study. LAMA4 is a member of the laminin family. Section 2.1 will provide a
summary of laminin function, structure, and disease associations. Section 2.2 will specifically
give a description of the LAMA4 gene, the main focus of the study. Section 2.3 will give a brief
synopsis of the relationship of genetic disorders that present with hearing impairment and
cardiovascular abnormalities. Section 2.4 will introduce gap junctions and the known functions
and disease associations. Section 2.5describes the connection of GJB2 to inherited deafness.
2.1 Laminin Family
Laminins are a family of extracellular matrix glycoproteins. They are essential for early
embryonic development and organogenesis and have crucial functions in several tissues including
muscle, nerve, skin, kidney, lung, and the vasculature (Durbeej 2010). They are the most
abundant structural non-collagenous glycoprotein present in basement membranes and vital to
cell recognition, adhesion, migration, and proliferation (Aberdam et. al. 2000).
Basement membranes are essential to the basic structure and mechanics of cells and
tissues, forming barriers between cell types, and regulating interactions with other cells (Suzuki
et. al. 2005). They are thin sheets of extracellular matrix that underlie epithelial and endothelial
cells and surround muscle cells, Schwann cells, and fat cells. Expression of laminins is tissue
specific and heavily determined by variations in the expression of the alpha chains (Durbeej
2010).
Laminins are composed of three chains: α, β, and γ. Each chain is encoded by its own
gene: LAMA (α), LAMB (β), or LAMC (γ). To date, five α (named α 1-5), three β (named β 1-3),
and three γ (named γ 1-3) chains have been identified. These chains assemble to create a cross
like laminin structure. Thus far 18alpha, beta, and gamma combinations (named laminin-1 to 18)
have been described (Durbeej 2010). The basic structures of the isoforms are relatively similar
(Figure 1). An alpha, beta, and gamma chain each make up a unique short arm of the protein. The
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chains coil together to form a long rigid rod-like structure creating a cruciform structure
(Iivanainen et. al.1995). N-terminal domains, which are important for laminin network formation
(Van Agtmael et. al. 2010) are present at the end of each short arm. The C-terminal domain of the
alpha chain is preceded by the coiled region. The alpha chain C-terminal domain consists of five
globular domains known as the laminin G (LG) domain. These globular domains are responsible
for much of the binding interactions with cellular receptors. Eight laminin isoforms that contain
α3A, α4, β3, and / or γ2 have a truncated arm due to a shorted N-terminus (Figure 1).

a)
b)
Figure 1. Basic structure of a laminin. Blue circles represent the N-terminal domains of each
chain. White circles are other globular domains. The black circles at the base of the figure
represent the LG domain. G domains are numbered sequentially (LG1-5) from the base of the
coiled region. a) General laminin structure. b) Laminin composed with a truncated alpha chain
(Model adapted from Belkin et. al. 2000, Tunggal et. al. 2000, Van Agtmael et. al. 2010, Durbeej
2010)
Interactions with laminins are detrimental for basement membrane formation, tissue
integrity, and biological processes. The LG domains bind to many proteins: heparin and sulfatides
presumably bind the LG domains of all α chains (Durbeej 2010). The three main cellular
receptors for laminins are integrins, dystroglycan, and syndecans. (Suzuki et. al. 2005, Durbeej
2010). Laminin - integrin binding regulates cell motility, survival, and proliferation. An inability
of laminins to interact with syndecans compromises basement membrane formation in
development.
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Several diseases of the skin, muscle, and nerve are associated with laminins, either
attributed to a defect in the laminin itself or the cellular receptors. Congenital muscular dystrophy
is caused by the lack of laminin and alpha-dystroglycan-glycoprotein complex binding due to
complete or near-complete deficiencies in laminin alpha2 (Suzuki et. al. 2005, McGowan et. al.
2000). Junctional epidermolysis bullosa (JEB) causes blistering of the skin in response to trauma
or friction and severe cases can be fatal in first year of life. It is caused by mutations in the three
genes LAMA3, LAMB3, and LAMC2 that are responsible for encoding the protein chains of
laminin-5 (McGowan et. al. 2000). Mutations in LAMB2 leading to a deficiency of the laminin
beta 2 chain contribute to the development of Pierson syndrome which causes ocular anomalies
contributing to renal failure and loss of vision (VanDeVoorde et. al. 2006, Van Agtmael et. al.
2010). Relationships of LAMA1 and LAMA4 with rheumatoid arthritis and osteoarthritis have
been examined (Salmon 1984, Fuerst et. al. 2010). Additionally, the relationship with laminin and
Alzheimer’s disease is currently under investigation (McGowan et. al. 2000).
In summary, the laminin family is not only important to the structure and organization of
muscle and tissue. Defects in the genes chains can produce debilitating or even fatal functional
problems.
2.2 LAMA4
The human LAMA4 gene encodes the protein laminin alpha 4. It is located on
cytogenetic band 6q21. Although countless studies have shed light on the functions of laminin
alpha 4, its exact function has eluded researchers (Stelzer et. al. 2012). It is predominantly located
in the endothelial basement membranes of blood vessels. The main expression sites include:
smooth muscle, fat, peripheral nerve neuromuscular junction, retina, and the central nervous
system (Durbeej 2010). Research has indicated that LAMA4 is also strongly expressed in the
adult heart, lung, ovary, small and large intestines, placenta, and liver (Iivanainen et. al. 1995).
Mouse studies have been conducted to determine expression and function. These studies show it
is also highly expressed in the aortic endothelium, endocardium and endothelium of blood vessels
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(Freiser 1997), and cardiac muscle cells (Liu et. al. 1996) as in human, suggesting outcomes of
LAMA4 studies with mouse models are relevant to human.
The structure of laminin alpha 4 is similar to other laminins. It has the closest
resemblance to the alpha 3 chain however it is also homologous to regions in the alpha 1 and 2
chains. The short arm is closest in homology to laminin alpha 1 (49.3% sequence identity)
although it is truncated at the N-terminal domain (Stelzer et. al. 2012, Iivanainen et. al. 1995).
LAMA2 and LAMA4 also demonstrate homologies in the long arm and LG domain in that they
are coded by a similar number of exons with few rearrangements. Six of the exons that code for
these regions are identical in size and exhibit conserved protein motifs (Richards et. al. 1997).
Integrins α3β1, α6β1, αvβ3 (Suzuki 2005, Gonzales 2002, Lian et. al. 2006) and the
syndecans act as cellular receptors for laminin alpha 4. Integrin interactions regulate cell motility,
survival, and proliferation. Interactions with syndecans are involved in cell signaling, adhesion
and migration in tumors and wound edges (Suzuki 2005).
Laminin alpha 4 is the alpha chain subunit that combines with beta and gamma chains to
form laminin isoforms laminin-8(α4, β1, γ1),-9(α4, β2, γ1) and -14(α4, β2, γ3). Research has
described its involvement in regulating endothelial cell survival through growth and proliferation
and LAMA4 plays an integral part in proper development of vasculature and structural integrity
of newly formed capillary basement membranes. Deletion of the alpha 4 protein in mice is not
lethal but leads to impaired microvessel maturation and cardiomyopathy (DeHahn et. al. 2004,
Lian et. al. 2006, Thyboll et. al.2001, and Knöll et. al. 2007). It has been shown to compensate in
the absence or reduced expression of other laminins such as laminin alpha2 (Ringelmann et. al.
1999).
To date, no specific human disease has been associated with the laminins containing the
alpha 4 chain, although mutations in the alpha 4 chain have been characterized in human
cardiomyopathy (Knöll et. al. 2007). Over-expression of laminin-8 in human dermal
microvascular endothelial cells has been related to promotion of angiogenesis related functions

10
(Lian et. al. 2006). The function of Laminin-14 expressed in the developing retina could be
involved in the formation or stabilization of synapses in the CNS, in particular during the
differentiation of the nervous system in development (Libby et. al. 2000).
2.3 Hearing Loss and Cardiac Abnormalities
Several genetic disorders present with phenotypes that include both hearing impairment
and cardiovascular abnormalities due to mutual developmental controls (Table 2). More than 100
genes associated in genetic hearing impairment are also associated to congenital and progressive
cardiac abnormalities. These genetic disorders present many modes of inheritance including
matrilineal, de novo dominant mutations, genomic disorders, chromosomal disorders, and familial
dominant; autosomal-recessive means. The types of genes that are associated with both
phenotypes are involved in transcription factors, chromatin remodeling, signal transduction
pathways, ion channels, extracellular matrix proteins, among others (Belmont et. al. 2011).
Genomic Disorder

Hearing/Ear association

Cardiovascular Abnormality

Tetralogy of Fallot, interrupted aortic arch type B,
DiGeorge Syndrome & 22q11 Deletion Otitis media, sinorhinitis, hearing loss double outlet right ventricle, perimembranous
Dialated cardiomyopathy, left ventricular
1p36 Deletion Syndrome
Deafness
noncompaction, ventricular septal defects
6p24 Deletion Syndrome

Deafness, auditory hypersensitivity

Williams Syndrome

Aortic valve abnormalities
Supravalvar aortic stenosis, branch peripheral
Otitis media, conductive hearling loss pulmonary arterial stenosis

Long QT syndrome

Congenital deafness

Heart arrhythmia

Leopard Syndrome

Sensorineural deafness

Hypertrophic cardiomyopathy

Alstrom Syndrome

Sensorineural hearing loss

Osteogenesis Imperfecta

Sensorineural hearing loss

Dialated cardiomyopathy
When present pathology of left-sided cardiac
valves, aortic root and ascending aorta.

Table 2. Genomic disorders with both hearing impairment and cardiovascular defects (Belmont
et. al. 2011).
2.4 Gap Junctions
The gap junction gene family encodes Connexin proteins that form permeable channels
known as gap junctions that connect the cytoplasm of adjacent cells. They regulate cell to cell
communication by allowing ions and small molecules to pass through. The type of molecules or
ions that pass through the gap channel facilitates the electrical and biochemical signals sent
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between cells and excitable tissues. Distribution of the twenty Connexin isoforms is tissue
specific, however many cell types express multiple isoforms (Mammano 2000).
Mutations in gap junctions have been associated with several human pathologies. GJA1
is integral in the synchronized contraction of the heart and in embryonic development (Stelzer et.
al. 2012). Mutations in this gene have been associated with severe heart malformations (Dasgupta
et. al. 2001). Mutations in gap junction genes, GJB3 and GJB2 have also been associated with
skin disorders such as Erythrokeratodermia variabilis (Gottfried et. al. 2002) and Vohwinkel
syndrome (Mammano 2000). Charcot–Marie–Tooth disease, linked to mutations inGJA1, causes
the degeneration of the peripheral nerve which leads to muscle atrophy, sensory disturbance,
hyporeflexia, and foot deformities (Lin P.et. al. 2010).
2.5GJB2
Connexin 26 is encoded by the GJB2 gene. GJB2 is located at cytogenetic band 13q11. It
is comprised of two exons, one of which contains the coding sequence (Kemperman et. al. 2002).
Variants in the GJB2 genes are responsible for up to 50% of autosomal recessive nonsyndromic
deafness in many world populations (Snoeckx et. al. 2005). Specifically, the deletion of a
gaunonsine nucleotide at position 30 or 35 is the most frequently occurring of the mutations in
GJB2 responsible for a deaf phenotype to be presented (Kemperman et. al. 2002).
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CHAPTER 3. MATERIALS AND METHODS
3.1 Approach
A systematic approach was designed to efficiently and effectively search for genetic
variants that may be causative or contributory to HLHS in the proband. This method begins with
high throughput sequencing and the subsequent integration of various bioinformatics tools to
analyze and investigate the relationship of these finding to the syndrome in the proband (Figure
2).

Figure 2:Novel variant detection and disease association approach.
3.2 Justification of Methodology
Although 454 pyrosequencing is a very reliable method, errors do occur. The dominant
error type for the 454 platform is insertion-deletion, usually due to consecutive instances of the
same base. Another error type that is possible is the miscalling of a nucleotide
(Shendure&Ji2008). Sanger sequencing is a reliable method to validate pyrosequencing results
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and typically used as the secondary analysis method to verify variant identification. Primers can
easily be designed with publically available software from NCBI to flank the specific sequence
variants. Turnaround time is also rather quick and sample processing of small sample sets is
relatively inexpensive.
The mode of inheritance of HLHS is proposed to be autosomal recessive (Hinton et. al.
2007). Based on the rate of occurrence it is likely variants found in more than 1% of the general
population are not the cause of this syndrome, therefore, the novelty of the variant needs to be
verified before further investigation. Mutation prediction tools such as SIFT and PolyPhen are
publically available and include web-interfaces for small queries. These tools not only provide
that a specific variant is novel but also calculates the likelihood that the change from the reference
sequence is non-synonymous, damaging, or tolerated. The algorithms use structural and sequence
information to predict the impact of substitution on the structure and function of a protein.
Determining the conservation of the amino acid provides a measure its functional importance at
that position in the protein. Highly conserved amino acids are inferred as being more important to
the function of the protein.
Pathway analysis can provide insight and potential avenues to explore and aid in the
identification of genes and proteins associated with the etiology of a disease. Pathway-based
analysis can mark the genes associated with a disease or phenotype and separates them from false
positive hits and can also be useful in identifying biological pathways affected by the genes (Wu
2010). Pathway analysis has been implemented in many areas including cancer research (Wu
2010. Xiao et. al. 2011) and successfully identified significant group effects on several gene-gene
pathway interactions relevant to IBD. Ingenuity Pathway Analysis (IPA, Ingenuity® Systems) is
a commercially available tool and GeneMANIA (Warde-Farley et. al.2010) is free web-based
software. Both tools were used as confirmation of results. GeneMANIA was also implemented as
a quick scan for interactions.
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Homology modeling is also an effective method used to infer the effect of a single variant
in a gene. Mossé et. al. (2008) conducted a linkage study of twenty families with varying degrees
of confidence of inheritance of neuroblastoma predisposition genes. Probands were sequenced for
novel variants found in the anaplastic lymphoma kinase (ALK) gene. Homology modeling of the
wild type and mutant forms of the gene made it apparent that the structure was dramatically
altered due to the location of the mutations in an activation segment and in a glycine looping
region. This data along with other experimental data in the study made it possible for researchers
to determine that ALK is a critical neuroblastoma oncogene.
Pedigree studies have been an invaluable tool for the identification of causative and
contributive genes in genetic disease. Perhaps the most famous pedigree is one that illustrates the
inheritance of hemophilia in the family of Queen Victoria of England. Due to the well-mapped
pedigree, researchers have recently identified a mutation in the F9 gene on the X chromosome as
the causative gene responsible for hemophilia B in the Romanov branch of the royal family
(Rogaev et. al. 2009). Familial studies have also been integral to the discovery of the
Huntington’s disease gene HTT (Chial 2008), mutations causative to development of cystic
fibrosis (Danes et. al. 1977), and sickle cell anemia (Frenette et. al.2007). These types of studies
are useful in determining whether there is a genetic relationship involved in a disease even if it
does not tease out the causative genes. Hinton et. al. (2007) used family pedigree analysis to
determine hypoplastic left heart syndrome is heritable. In a study of 38 families affected by this
syndrome pedigree analysis supported that HLHS in almost entirely caused by genetic effects.
Extended pedigrees increase statistical power for gene discovery and represent a more
homogeneous and limited set of causative genes and pathways especially in complex traits such
as heart disease. Such complex traits tend to be common and cluster in families but do not always
follow clean Mendelian segregation patterns. They may be caused by many genes and affected by
multiple pathways in which multiple defects or mutations lead to the phenotypic variation.
Familial studies are advantageous in revealing underlying causes as they benefit from the shared
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genetic background and similar environmental exposures in comparison to studies with nonrelated cohorts (Borecki 2008).
3.3 Exome Capture
21µg of input DNA was used with the NimbleGen Sequence Capture Human Exome
2.1M array (Roche NimbleGen, Madison, WI). The Human Exome Array targets ~180,000
human protein coding exons and ~700 miRNA exons using 2.1 million long oligonucleotide
probes (>60mer) on a single microarray. The captured fragments were sequenced with Roche
protocol for Titanium chemistry on the 454 GS FLX instrument (Roche 454, Branford, CT). The
sequence reads were aligned to human genome reference sequence NCBI 36.3 and variants were
identified with Roche 454 gsMapper software.
Variants were annotated with a clinical in-house variant analysis platform, Carpe Novo,
to determine candidate mutations to investigate (Worthey et. al.2011). Carpe Novo incorporates
four stages of analysis. Primary analysis includes sequencing analysis. Secondary analysis is the
sequence alignment, variant calling, and the consideration of data from the sequencing run such
as depth of coverage and number of reads. Tertiary analysis consists of the annotation of variants.
Quaternary analysis involves running queries on the annotated data to further narrow the potential
candidate list (Worthey et. al.2011, Davies 2011).
3.4 Confirmation of Exome Sequencing Results.
Confirmation of the exome sequencing was a two part process. The first step in the
process was to design primers that would detect the variant found in exome sequencing. This step
involved submitting the nucleotide coordinates to validate the variant in build 36.3 with the NCBI
Map Viewer tool found at the following web address:
http://www.ncbi.nlm.nih.gov/projects/mapview/map_search.cgi?taxid=9606&build=previous
(Wolfsburg 2011). The second step was to verify the variants retained their novel and damaging
status from the initial date of analysis to the date of primer design.
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3.4.1 Primer Design
NCBI Primer-BLAST (http://www.ncbi.nlm.nih.gov/tools/primer-blast/) was used to
generate forward and reverse primers flanking each variant. To narrow in on the variant
nucleotide positions plus and minus 500 base pairs were entered in the Range Section. If initial
testing resulted in several bands, this length allowed for easier nested primer design. Primer Pair
specificity Checking parameters were as follows:
•
•
•
•

Specificity Check: enable search for primer pairs specific to the intended PCR product =
enabled.
Organism: 9609 (Human)
Database: Genome (reference assembly from selected organisms)
Primer specificity stringency: 2 total mismatches to unintended targets, including at least
2 mismatches within the last 5 base pairs at the 3’ end. Ignore targets that have 7 or more
mismatches to the primer (default)
Primer selection criteria required 2 mismatches to be present within 5 bases of the 3’ end

of the reverse primer. The more mismatches present for other products in the primer pair, the
more specific the primer is expected to be for the intended product. As several primers may
cover the area of interest, primers with the greatest number of mismatches with unintended
targets were selected. These mismatches on the end are to further ensure specific to the intended
target sequence. Single and nested primer pairs were designed to confirm the variants found in the
exome sequencing (Table 3).
PCRs were conducted for each variant primer set. 5ng of proband DNA sample was
denatured at 94°C for 15 minutes and amplified for 40 cycles, each consisting of 30 seconds at
95°C, 30 seconds at 53°C, and 45 seconds at 72°C, followed by a 10-minute extension at 72°C.
4µl of PCR product was visualized on a 2% agarose gel stained with ethidium bromide. PCR
product was cleaned by and ExoSAP-IT reaction and sent to Retrogen, Inc. (San Diego, CA) for
sequencing reactions. Sequencing results were analyzed with Sequencher DNA analysis software.
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Gene
Size (bp)
Taldo1 forward
782
Taldo1 reverse
KCNJ12 forward
630
KCNJ12 reverse
ARSD forward
332
ARSD reverse
GOLGB1 forward
271
GOLGB1 reverse
OR7C1 forward
322
OR7C1 reverse
CDC27 forward
260
CDC27 reverse
Taldo1 forward
163
Taldo1 reverse
KCNJ12 forward
232
KCNJ12 reverse
ARSD forward
120
ARSD reverse
GOLGB
123
GOLGB
OR7C1
121
OR7C1
CDC27
168
CDC27
MAGEC1 forward
719
MAGEC1 reverse
OR4C3 - 1 forward
605
OR4C3 - 1 reverse
OR4C3 - 2 forward
608
OR4C3 - 2 reverse
OR4C3 - 3 forward
606
OR4C3 - 3 reverse
AKAP13 forward
476
AKAP13 reverse
CD2BP2 forward
618
CD2BP2 reverse
LAMA4 forward
924
LAMA4 reverse
OR1J2 forward
668
OR1J2 reverse
OR52N2 forward
375
OR52N2 reverse

Sequence
GTGGGGAGCGGCCATTCGTC
GTGGGACGCACACGTGGGAG
TACGGGCTGCGCTGTGTGAC
GGGGCGTAGAGGGCACCTCA
TGGGTTGCTCCGTGACGTCA
GCGGGGATCACTGCCACCAC
CCACCCCTACCTGTGCAGGTTGT
ACTGATGGGAGCAAGAAAAACCAGC
AGGCCACCAGACTTGTCGCC
TCGAGCAGGGAACCCATGACACT
AGTACCAGCACCATCAATACGACTTTG
GTTCCCTGCAGCACACCAGGC
TCATAGTCAGGTGAACTGAG
TCACCCCCATTGCCTTTCTT
TAACCTGCGCAAGAGCCACA
AAAGTCGTCCGTCTCCAGGT
AACTGGGTGTAACCCCAGAG
GAACCACGGATTTGACTATT
AGGTTGTTCTGCCTGTGCCT
TGTAGAACTCTTGTCATGCTGA
ACCTAGAAGATGGTGTGGCT
TTGTGCTTTCTCCCAGCTGA
AATGTCTAGGATTGACTCTG
CAATATCATGTTCCCGTTGCA
TCCCCAGTCTCTTCTCCAGATTCCT
CCTCCCCCTGAGGAGGGCTC
ACACCTGCAGCATGCCTAGAACA
TGTTGTCTCCTGCACCTAGCACT
ACACCTGCAGCATGCCTAGAAC
CATGTTGTCTCCTGCACCTAGCAC
ACACCTGCAGCATGCCTAGAACA
TGTTGTCTCCTGCACCTAGCACT
GGGATACCCAGGAACGTGCGGA
CTGGGATTGCTGGAGGGGCG
CCCTCCAAGAGGGCTTGGGC
ACCCTGTGGCTGGGTCAGGG
TTCCAGCCTCCCTGTGGCCA
AGCAAGTTGTTTAGTTCACCCAAACCA
ACCAGAGCAGCGTGTCCGAGT
CCCTCAGGATGGTGGCCCCA
CCTGCCCTATTGCCGGGGGA
TGGGTTCATGGTAGGAGGCAGTAGC

Table 3.Primer pairs for PCR confirmation of variants.
3.4.2. Confirmation of Novel Status

Amino acid conservation among species was verified with mouse, rat, chick, and
zebrafish. UniProtKB identifiers for each species were retrieved from the UniProt Consortium
Protein Knowledgebase (Jain 2009, Magrane 2011). BLAST alignment with the clustalo
algorithm was conducted.
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The UCSC liftOver tool (Haussler 2006) enables researchers to translate nucleotide
positions aligned to previous builds in the NCBI reference genome to other or more current
releases. A BED file with the minimum of the following three fields: chromosome (chrom),
starting position of the chromosome (chromStart), and the ending position of the chromosome
(chromEnd) is required for submission to the tool (Hinrichs et. al. 2006). The start and stop
position of the chromosome(s) being queried are returned. The position of the variant of interest
is subtracted from the end position of the chromosome in the original assembly in order to
translate the updated coordinates in the queried assembly.
The NCBI37/hg19 nucleotide coordinate was used as search criteria to verify no SNP
data is associated with the variant. A SNP identification number is necessary for determining if a
SNP exists within dbSNP. Since the variants examined in this study were novel, there was no
SNP identification value. The coordinates of the variant and sequence were very useful in
confirming with NCBI whether a SNP had been identified with this variant and either missed by
the initial carpe novo analysis or updated since that original analysis.
SIFT analysis (Ng & Henikoff 2003) was repeated with the updated nucleotide
coordinates to ensure the novel and damaging status remained current. The chromosome number,
variant position, orientation and alleles were entered into the web based submission form. OMIM
Disease and Allele Frequencies (All HapMap Populations) output options were selected (Ng &
Henikoff 2003).
Polymorphism Phenotyping (PolyPhen) analysis was repeated using the amino acid
position and substitution. This pipeline calculates the potential impact of an amino acid
substitution on the structure and function of a protein. A numerical score ranging from 0.00-1.00
is returned from the input queries. The higher the score, the more likely the amino acid change is
damaging to the structure and function of the queried protein (Adzhubei et. al. 2010).
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3.5 Protein Model Development
Homology models of wild type and mutated genes were generated with MODELLER
v9.10 (Šali 1993) and PyMOL v0.99 software (The PyMOL Molecular Graphics System). Genes
with resolved crystal structures were aligned with the sequences of the mutated genes with
BLAST. The most homologous crystal structure found in Protein Data Bank (pdb - Bernstein
1977) and the Protein Families Database (Pfam - Punta et. al.2012) was used as the backbone for
the mutated gene to be threaded upon. The .pdb file was loaded into PyMOL with the PDB Plugin Loader Service. All hydrogen, water, and sugar molecules were deleted as they are not
necessary for the MODELLER software. Blastp alignment was conducted to verify the sequence
segment to utilize for the wild type and mutated models.
The MODELLER align2d.py script (Altschul 1990) was used to generate the final
alignments to the known structures. The alignment generated by this step is input to the Modelsingle.py script for calculation of the 3D models in .pdb format. These models are viewed in the
PyMOL software and analyzed. The model that retained the most structural homologies within
the model set was selected as the final representative model.
3.6 Pathway Analysis
Two methods of pathway analysis were conducted with the IPA tool (Ingenuity®
Systems). The first method generated a general sense of the gene neighborhoods to explore if any
of the candidate genes are closely related in a pathway. Each gene was queried under the Genes
and Chemicals search. The interaction network option was selected to view the figure
representing the relations and the build tool was used to grow pathways from the query gene.
Individual queries were run based on indirect/direct interactions and relationship types. Examples
of interactions used as ‘grow’ criteria were: direct, protein-protein interaction, indirect proteinprotein interaction, direct regulation of binding, etcetera. All relationship query types were
examined in order to get a full picture of all possible relationships.
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The interaction neighborhoods were exported to a .csv file which was then modified to
include the gene queried, direct or indirect interaction, and relationship type. The .csv files were
merged with a python script. The combined file was used to determine if any of the neighborhood
genes overlapped with other gene queries. The overlapping genes were then compared to the
exome date to determine if variants were found in these genes but then not considered for
evaluation due to a non-damaging or non-novel status. An additional list of genes reported to be
involved with CHD, HLHS, and Turner’s syndrome were also examined in this manner (Table 4).
Gene
ATRX
BCOR
EHMT1
ERBB4
FKBP6
FLNA
FOXC1
GATA4
GJA1
GPC3
HAND1
MID1
MYH11
NKX2.5
NOTCH1
SOX7
ZIC3

Association
Turner's syndrome
Turner's syndrome
CHD
CHD
Turner's syndrome
Turner's syndrome
HLHS
CHD
HLHS
Turner's syndrome
HLHS
Turner's syndrome
CHD
HLHS
HLHS
CHD
Turner's syndrome

Reference
Tomita-Mitchell 2012
Tomita-Mitchell 2012
Kleefstra 2006
McBride 2011
Tomita-Mitchell 2012
Tomita-Mitchell 2012
Grossfeld 2009
Draus 2009, Rajagopal 2007, Tomita-Mitchell 2007, Tomita-Mitchell 2012
Grossfeld 2007, Grossfeld 2009, Hinton 2009
Tomita-Mitchell 2012
Grossfeld 2009, Reamon-Buettner 2008
Tomita-Mitchell 2012
Zhu 2006
Elliott 2003, Grossfield 2007, Grossfeld 2009, McBride 2008, Stallmeyer 2010
Grossfeld 2009, Grossfeld 2007, McBride 2008
Wat 2009
Tomita-Mitchell 2012

Table 4. Genes with cardiac or Turner’s syndrome associations. These genes were used in IPA
pathway analysis. See bibliography for references.
The second method of IPA network analysis was to generate a graphical representation of
the molecular relationships between the candidate genes and HLHS. Cardiac disease and
functions such as: Hypertrophy of cardiac muscle, HLHS, hypertrophy of heart, congestive heart
failure, heart disease, coronary disease, and left ventricular dysfunction were overlaid to visually
determine if any the candidate genes have a cardiac related function or were closely related to
genes associated with HLHS.
Additional pathway analysis was conducted with GeneMANIA (Warde-Farley et.
al.2010) to examine potential interactions of candidate genes in the study, known cardiac genes,
and gap junction genes. GeneMANIA utilizes publicly available genomic and proteomic data sets
such as GEO, BioGRID, Pathway Commons, and I2D for prediction of functional relationships or

21
shared properties of genes. It supports data for Arabidopsis thaliana, Caenorhabditis elegans,
Drosophila melanogaster, Mus musculus, Homo sapiens, and Saccharomyces cerevisiae (WardeFarley et. al. 2010). GeneMANIA suggests annotations for genes based on Gene Ontology term
enrichment of highly interacting genes with the query gene and is a gene recommendation system
(The Gene Ontology Consortium 2000). The queries were weighted according to the Gene
Ontology (GO) biological function weighting method. This weight reflects the data source
relevance for predicting the function of interest (Warde-Farley et. al. 2010). GeneMANIA output
was used in conjunction with IPA analysis to verify and generate hypothesis of gene
relationships.
3.7 Family Pedigree Analysis
To examine the potential relationship of the CHD and deaf phenotype in the family,
primers designed and published by Snoeckx et. al. for detecting the connexin26 deletion: Cx26F
(5’-TCTTTTCCAGAGCAAACCGC-3’) /Cx26R (5’- GGGCAATGCGTTAAACTGGC-3’)
were used in Sanger sequencing reactions with all available family DNA samples. DNA sample
was denatured at 94°C for 15 minutes and amplified for 40 cycles, each consisting of 30 seconds
at 95°C, 30 seconds at 63°C, and 45 seconds at 72°C, followed by a 10-minute extension at 72°C.
4µl of PCR product was visualized on a 2% agarose gel stained with ethidium bromide. PCR
product was cleaned by and ExoSAP-IT reaction and sent to Retrogen, Inc. (San Diego, CA) for
sequencing reactions. Sequencing results were analysis with Sequencher DNA analysis software.
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CHAPTER 4. RESULTS AND DISCUSSION
4.1 Exome Sequencing and Sanger Sequencing Analysis
Exome sequencing resulted in an average depth of 36X coverage. Enrichment was
approximately 75-fold. 60% of reads mapped to targeted regions and more than 99% of the
intended targeted region was covered. Carpe novo data analysis identified more than 13,000
coding differences compared to the human genome reference (NCBI36/hg18) were found. More
than 1400 of these coding differences (variants) were novel (Worthey et. al.2011).
PolyPhen (Adzhubei et. al 2010) and SIFT (Ng &Henikoff 2003) analyses were then
utilized to further prioritize variants. The more conservative PolyPhen analysis was conducted
first due to the ability to automate the process in house. Non-synonymous sequence variants in
approximately 140 genes were predicted to be “damaging”. This data set was then entered into
SIFT (www.http://sift.jcvi.org/) and further reduced to 13 genes when sorted by status according
to SIFT. The variant positions and nucleotide results were confirmed against NCBI map viewer
human build 36.3 before confirmation with Sanger sequencing.
PCR Primer sets for variants found in genes TALDO1, KCNJ12, ARSD, LAMA4, and
AKAP13 generated clean results when visualized on the 2% agarose gel, reducing the number of
variants of interest to five (Figure 3). The DNA samples of immediate family members: father,
mother, unaffected sibling, and fetal tissue were screened. Sanger sequencing results were aligned
and analyzed with Sequencher DNA Sequencing Software, further reducing the number of
variants to potentially investigate (Table 5).
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Figure 3. Gel Electrophoresis results of TALDO1, KCNJ12, ARSD, LAMA4, and AKAP13.
These products were sent for sequencing confirmation. Lane 1: 100bp DNA Ladder (Invitrogen)
Lanes 2-5: Negative controls (TALDO1, KCNJ12, ARSD, AKAP13, LAMA4). Lanes6-10:
Positive Negative controls (TALDO1, KCNJ12, ARSD, AKAP13, LAMA4). Lanes 11-15:
TALDO1. Lanes16-20: KCNJ12. Lanes21-24: ARSD. 100bp DNA Ladder
(Invitrogen).Lanes26-29:AKAP13. Lanes30-33: LAMA4.100bp DNA Ladder (Invitrogen)
Sample order is: Proband, Father, Mother, Unaffected Sibling, Fetal tissue.

Table 5.Sanger sequencing confirmation. Nucleotides listed in the ‘Expected’ column are
expected according to the NCBI36/hg18 assembly. Nucleotides listed in the ‘454’ column
indicate nucleotide variants found in the exome sequencing reaction. Primer sets for variants
found in genes ARSD, Taldo1, and KCNJ12 did not confirm the variants found in the exome
sequencing reaction.
The AKAP13 PCR reaction confirmed the exome sequencing finding of a nucleic acid
change from cytosine to thymine at position 83,924,813 (NCBI36/hg18 assembly). The initial
decision was to not pursue the variant in this gene as the mode of inheritance is not
straightforward since all family members except the mother carry the variant. A point of interest
for this variant is that there is a second peak at this position in all members that carry the
mutation. A cytosine peak is present that is approximately 10% the height of the thymine peak
(Figure 4).
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Figure 4. Chromatograms of AKAP13 and LAMA4 Sanger sequencing results: a.AKAP13
cytosine present in DNA sequence of the mother. b. Thymine variant found in other family
members – note presence of slight cytosine peak. c. LAMA4 cytosine present in father and
unaffected sibling. d. Heterozygous variant in proband, mother, and fetus.
The list of variants of interest ultimately was reduced to the variant found in LAMA4 at
position 112570046(NCBI36/hg18 assembly). The chromatograms of the proband, mother, and
fetus indicate they all are heterozygous for the LAMA4 variant (guanine) and expected nucleotide
(cytosine). The father and unaffected sibling both have a single cytosine peak at this position
(Figure 2c, 2d). PCR sequence analysis of extended family members including a non-HLHS
sibling, maternal grandparents, maternal half great uncle and aunt, maternal aunt, & maternal
cousin showed that the non-HLHS sibling and maternal grandmother are also heterozygous for
the LAMA4 variant.
4.2 Variant Pathway Analysis
The 13 genes of interest were analyzed through the use of IPA (Ingenuity® Systems, Inc.
Redwood City, CA). Output files were combined and compared to find genes that overlapped
among the twelve candidate’s gene neighborhoods. Some neighborhood overlaps did occur,
however further pathway analysis did not indicate a clear relationship to cardiac defects (Table
6). Variants in IL2 (interleukin 2 - cytokine) and SKIL (ski-like oncogene) were found in the
exome sequencing results but were not novel or predicted as damaging. GeneMANIA queries of
these genes, with LAMA4 did not result in physical or pathway relationships.
FOXM1 (cell proliferation), TNF (tumor necrosis factor), and ZHX1 (zinc finger and
homeobox) were shared in LAMA4 neighborhoods but no mutations in these genes were found in
the exome sequencing. These genes do not have implied cardiac functions, however to
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potentially sift out potential relationships, a GeneMANIA query was run to screen for interactions
with HLHS genes GJA1 and PDE5A to potentially view pathway connections that could be
related to HLHS and no significant relationships were returned.
Symbol
FOXM1
FOXM1
FYN
FYN
HNF4A
HNF4A
IL2
IL2
SKIL
SKIL
TNF
TNF
ZHX1
ZHX1

Family
transcription regulator
transcription regulator
kinase
kinase
transcription regulator
transcription regulator
cytokine
cytokine
transcription regulator
transcription regulator
cytokine
cytokine
transcription regulator
transcription regulator

From Neighborhood Relationship Type
CDC27
PP
LAMA4
PD
CD2BP2
RB
CDC27
PP
AKAP13
MB
KCNJ12
PD
AKAP13
LO
CD2BP2
LO
CDC27
PP
GOLGB1
PP
LAMA4
E
TALDO1
E
LAMA4
PP
TALDO1
PP

Interaction
D
D
I
D
D
D
I
I
D
D
I
I
D
D

Table 6. Overlapping genes found in query neighborhoods. IL2 and SKIL Genes in column one
are also found to have non-novel mutations in the exome sequencing results. Key: PP: proteinprotein binding, PD: protein-DNA binding, RB: regulation of biding, MB: Group/complex
membership, LO: localization, E: expression (includes metabolism/synthesis for chemicals). D:
direct interaction, I: indirect interaction.
The outputs from the variant neighborhood analysis were also compared to the gene list
in Table 3. Overlapping genes were compared to the exome sequencing data to determine if
variants were found but not considered for evaluation due to a non-damaging or non-novel status.
The purpose of this comparison is to ascertain if the novel mutation alone is not responsible for
the development of HLHS but coupled with other mutations (possibly not novel) HLHS could
develop. PRKCA was found in these results, the 13 genes of interest neighborhood output, and
454 exome results (Table 7).
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Output
Variants of
Associated
Exome
Gene
Interest
Genes
variant
CDKN1A
CDC27
NOTCH1
no
CTNNB1
AKAP13
GJA1
no
ESR1
AKAP13
ERBB4
no
IL5
AKAP13
GATA4
no
ITGB1
LAMA4
FLNA
no
ITGB3
LAMA4
FLNA
no
PRKCA
AKAP13
GJA1
YES
SMAD3
CDC27
NOTCH1
no
SRF
AKAP13
MYH11
no
TP53
LAMA4
NOTCH1
no
Table 7. Common genes in exome data and additional gene list. PRKCA was found in both the
variant gene list and the additional gene list neighborhoods (Table 4). PRKCA was found to have
a variant in the exome sequencing data. The PRKCA variant found in the exome sequencing
results in the nonsynonymous coding change of amino acid valine (nonpolar neutral) to isoleucine
(nonpolar neutral). The SIFT score is 1 deeming the change tolerated. The mutation is identified
with dbSNP ID rs6504459 and therefore not novel.
PRKCA is a kinase that has been reported to play roles in many different cellular
processes, such as cell adhesion, cell transformation, cell cycle checkpoint, and cell volume
control (Stelzer et. al. 2012). In epithelial studies it has been indicated that the failure to downregulate PRKCA increases leakiness of tight junctions (Mullin et. al. 2000). It also promotes
angiogenic activity of human endothelial cells (Xu et. al. 2008) implying a potential relationship
with GJA1 and LAMA4. It also has been studied in regards to its role in cardiac function.
PRKCA controls myocardial contractility in mice and rats with cardiac disease. Knockout studies
have shown null PRKCA mice have enhanced cardiac contractility and reduced susceptibility to
heart failure whereas over-expression showed decreased cardiac contractility, ventricular dilation,
and secondary hypertrophy (Ladage et. al. 2011)
The GeneMANIA query of PRKCA, known HLHS gene GJA1, and candidate genes
LAMA4, and AKAP13 with Gene Ontology (GO) biological function based weighting returned
one direct genetic interaction between LAMA4 and AKAP13 (Figure 5). This interaction returned
the lowest weight of all interactions between query genes (4.55E-04) and was supported by one
publication (Lin A. et. al. 2010). A similar pathway query did not show connectivity among the
genes except in the case of LAMA4 and PRKCA, and again was the weakest interaction in the

27
network query (0.005128629). This pathway relationship was only supported by one publication.
Physical Interactions accounted for 82.62% of the network interactions in this query meaning any
interaction with these genes is more likely to be physical rather than pathway or genetic.
Although the weights of the predicted interactions among the query genes were not exceptionally
high, interactions between PRKCA and AKAP13 and PRKCA and GJA1 were supported by iRefBIND, Bio-Grid-small scale studies, IREF-OPHID, and iRef -small scale studies. These genes
may be found to indirectly work together in the formation of HLHS when more data is published.

Figure 5. Genetic, pathway, and physical interactions. LAMA4, GJA1, PRKCA, and AKAP13(as
predicted by GeneMANIA)share physical, pathway, and genetic interactions.
The second method of IPA network analysis generated a graphical representation of the
molecular relationships between the twelve genes of interest and HLHS or cardiac disease or
function. The input for this representation were the original thirteen genes, GJA1, and PDE5A.
GJA1 and PDE5A were included as they were returned from an IPA Functions and Diseases
query of HLHS. Cardiac associations shown in Figure 6 were overlaid to visually determine if
any the genes have a cardiac related function. This visual representation indicates LAMA4 and
AKAP13 are involved in several cardiac related diseases functions and therefore could potentially
be involved in the development of HLHS in this family.
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Figure 6.Variant and Cardiac Relationships. Disease Molecules and disease are represented as
nodes and the biological relationship between two nodes is represented as an edge (line). All
edges are supported by at least one reference from the literature, from a textbook, or from
canonical information stored in the Ingenuity Knowledge Base. Molecule nodes are displayed
using various shapes that represent the functional class of the gene product. Function / disease
nodes are oval (© 2000-2010 Ingenuity Systems).

4.3. Novel Variant Selection
Pathway analysis and Sanger sequencing confirmation of the first five family members
that provided DNA samples indicated that LAMA4 was a potential candidate to play a role in the
development in HLHS. Literature searches supported that there may be involvement of LAMA4
with HLHS due to the integral role of LAMA4 in cell communication, scaffolding, development,
and the circulatory system (refer to Chapter 2.2).
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4.3.1 Justification
Several hypotheses regarding the development of HLHS suggest the mutation found in
the LAMA4 gene may be causative or contributive to the development of CHD in this family.
One accepted hypothesis, supported by research in embryonic chick, states that HLHS develops
late in embryogenesis as a result of embryonic alterations in blood flow, such as premature
narrowing of the foramen ovale and aortic stenosis (Hinton et. al. 2007, Dasgupta et. al. 2001).
Given the alpha-4 subunit is involved in angiogenesis and endothelial branching morphogenesis
(a component of blood vessel development) it is feasible to consider the likelihood that LAMA4
plays a role in the development in HLHS. This is further supported by a second hypothesis that
suggests that the extracellular matrix protein signaling molecules could serve as HLHS causing
genes (Hinton et. al. 2007).
LAMA4 is located in close proximity to another region also related to cardiac defects on
chromosome 6. A family-based genome-wide linkage analysis performed on families with an
HLHS or bicuspid aortic valve (BAV) proband linked HLHS to chromosome 6q23 (Hinton et. al.
2009). The 6q22-23 region is also linked to familial dilated cardiomyopathy and conduction
disease (Messina et. al. 1997). Char syndrome is caused by mutations in TFAP2B located in
region 6p12-21.1. Cardiovascular abnormalities such as patent ductus arteriosus (the connection
between the aorta and the pulmonary artery does not close after birth) are commonly present in
patients with this syndrome (Vaughan & Basson 2000). Perhaps the proximity of LAMA4 to
these regions can be considered as a risk factor.
Several studies have linked LAMA4 to cardiovascular development, function, and
dysfunction. Knöll et. al. (2007) discovered two novel amino acid mutations in the LAMA4 gene
that lead to a loss of integrin binding capacity. They discovered that a function of integrin –linked
kinases is to maintain morphology of the ventricle during embryonic development and to
maintain cardiomyocyte shape. This function is dependent on the LAMA4 gene suggesting that
mutations in this gene causing conformational changes will interfere with the interaction of
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endothelial cell and cardiomyocytes with the extracellular matrix. This interference may cause
cardiomyopathy and ultimately lead to death (Knöll et. al.2007)
Studies with model organisms such as chick and mouse have been conducted to better
understand human cardiac development. Nath et. al. (2009) determined that endothelial cell
differentiation is a critical factor in heart development. These studies have also indicated that
there are overlapping developmental pathways in vasculature and heart. Additional studies with
laminin alpha-4 deficient mice have demonstrated an ischemic cardiac phenotype caused by a
mutation in the laminin alpha 4 chain. Although mice survive development, 20% of the null mice
died in the perinatal stage. Surviving litter mates did not express a notable phenotype but had
increased frequency of sudden death. The null laminin alpha-4 mice possessed altered
extracellular matrix structures that created an inefficient flow of blood to the heart due to cardiac
hypertrophy and cardiac dysfunction (Wang et. al. 2009). Additional studies show null laminin
alpha-4 mice leads to impaired blood vessel maturation. Capillary basement membranes are weak
causing fatal hemorrhaging in 50% of the null laminin apha-4 mice (Thyboll et. al. 2001). This
discovery could be pertinent if HLHS is acquired due to restriction of left heart blood flow in
embryogenesis as suggested by Dasgupta et. al. (2001).
4.3.2. Supporting Pathway Analysis
Pathway analysis with IPA (Ingenuity® Systems) supported the pursuit of LAMA4 in
regards to HLHS. Figure 6 is a graphical representation of the thirteen genes of interest and their
relationships to cardiovascular disease and system development and function. Each relationship
has a p-value calculated using the right-tailed Fisher Exact Test (Table 8). The p-value is a
measure of the likelihood that the association between the molecules and a given function is due
to random chance. The smaller the p-value, the less likely the association is random, and the more
significant the association. In general p-values less than 0.05 indicate a statistically significant,
non-random association (Ingenuity® Systems, www.ingenuity.com). The calculated p-values for
the data set of the twelve genes of interest including GJA1 and PDE5A statistically support the
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importance of the role of LAMA4 in the cardiovascular system. It was not indicated to have a
relationship with HLHS; however, the other relationships within the cardiovascular system may
lead to causal or contributory factors.
© 2000-2012 Ingenuity Systems, Inc. All rights reserved.
Category
Function
Cardiovascular Disease
hypoplastic left heart syndrome
Cardiovascular System Development and Function morphology
Cardiovascular Disease
hypertrophy
Cardiac Hypertrophy
hypertrophy
Cardiovascular System Development and Function morphology
Cardiovascular System Development and Function coupling
Cardiovascular System Development and Function migration
Cardiovascular System Development and Function proliferation
Cardiac Proliferation
proliferation
Organ Development
development
Cardiovascular Disease
atherosclerosis
Cardiovascular Disease
endocardial cushion defect
Cardiovascular System Development and Function communication
Organ Development
development
Cardiovascular System Development and Function contraction
Cardiovascular Disease
angina pectoris
Cardiovascular System Development and Function branching
Cardiovascular Disease
congestive heart failure
Cardiovascular Disease
cerebral vasospasm
Cardiac Degeneration
degeneration
Cardiovascular Disease
heart disease
Cardiovascular Disease
atherosclerosis
Cardiovascular Disease
coronary disease
Cardiovascular Disease
cardiomyopathy
Cardiovascular Disease
atherosclerosis
Cardiovascular Disease
patent ductus arteriosus
Cardiovascular Disease
left ventricular dysfunction
Cardiovascular Disease
intermittent claudication
Cardiovascular Disease
ventricular fibrillation
Cardiovascular Disease
stroke
Cardiovascular Disease
valvulopathy
Cardiovascular Disease
cardiac arrest
Cardiovascular System Development and Function looping morphogenesis
Organ Development
looping morphogenesis
Cardiovascular Disease
chronic stable angina
Organ Development
gonadogenesis
Cardiovascular System Development and Function contractility
Cardiovascular System Development and Function morphogenesis
Cardiovascular Disease
aortic stenosis
Cardiovascular Disease
systemic sclerosis
Cardiovascular Disease
endothelial dysfunction
Cardiovascular Disease
ischemic cardiomyopathy
Cardiovascular Disease
pulmonary hypertensive arterial disease
Cardiovascular Disease
ventricular tachycardia
Cardiovascular Disease
preeclampsia
Cardiovascular System Development and Function contractility
Cardiovascular System Development and Function function
Organ Development
function
Cardiovascular Disease
coronary artery disease
Cardiac Arteriopathy
coronary artery disease
Cardiovascular System Development and Function vasoconstriction
Cardiovascular Disease
hypertension

Function Annotation
p-value Molecules
# Molecules
hypoplastic left heart syndrome
1.66E-06 GJA1, PDE5A
2
morphology of blood vessel
8.92E-05 GJA1, LAMA4
2
hypertrophy of cardiac muscle
1.36E-04 AKAP13, PDE5A
2
hypertrophy of cardiac muscle
1.36E-04 AKAP13, PDE5A
2
morphology of coronary artery
5.46E-04 GJA1
1
coupling of proepicardial cells
5.46E-04 GJA1
1
migration of proepicardial cells
5.46E-04 GJA1
1
proliferation of proepicardial cells
5.46E-04 GJA1
1
proliferation of proepicardial cells
5.46E-04 GJA1
1
development of primary ovarian follicle
5.46E-04 GJA1
1
atherosclerosis of abdominal aorta
1.09E-03 GJA1
1
endocardial cushion defect
1.09E-03 GJA1
1
communication of endothelial cell lines
1.09E-03 GJA1
1
development of secondary ovarian follicle 1.09E-03 GJA1
1
contraction of heart
1.49E-03 GJA1, KCNJ12
2
angina pectoris
1.69E-03 KCNJ12, PDE5A
2
branching of endothelial cell lines
2.18E-03 LAMA4
1
congestive heart failure
3.03E-03 KCNJ12, PDE5A
2
cerebral vasospasm
3.81E-03 PDE5A
1
degeneration of cardiomyocytes
4.90E-03 LAMA4
1
heart disease
6.17E-03 AKAP13, GJA1, KCNJ12, LAMA4, PDE5A
5
atherosclerosis of aortic root
8.16E-03 GJA1
1
coronary disease
8.49E-03 AKAP13, KCNJ12, LAMA4, PDE5A
4
cardiomyopathy
9.57E-03 GJA1, PDE5A
2
atherosclerosis
1.11E-02 AKAP13, GJA1, LAMA4, PDE5A
4
patent ductus arteriosus
1.25E-02 PDE5A
1
left ventricular dysfunction
1.36E-02 PDE5A
1
intermittent claudication
1.41E-02 PDE5A
1
ventricular fibrillation
1.41E-02 KCNJ12
1
stroke
1.44E-02 GJA1, PDE5A
2
valvulopathy
1.73E-02 PDE5A
1
cardiac arrest
1.79E-02 PDE5A
1
looping morphogenesis of heart
2.05E-02 GJA1
1
looping morphogenesis of heart
2.05E-02 GJA1
1
chronic stable angina
2.16E-02 KCNJ12
1
gonadogenesis
2.29E-02 GJA1, OR7C1
2
contractility of cardiomyocytes
2.32E-02 LAMA4
1
morphogenesis of blood vessel
3.01E-02 GJA1
1
aortic stenosis
3.07E-02 PDE5A
1
systemic sclerosis
3.07E-02 PDE5A
1
endothelial dysfunction
3.12E-02 PDE5A
1
ischemic cardiomyopathy
3.44E-02 PDE5A
1
pulmonary hypertensive arterial disease
3.54E-02 PDE5A
1
ventricular tachycardia
3.86E-02 KCNJ12
1
preeclampsia
3.91E-02 PDE5A
1
contractility of heart
4.12E-02 PDE5A
1
function of heart
4.18E-02 LAMA4
1
function of heart
4.18E-02 LAMA4
1
3
coronary artery disease
4.30E-02 AKAP13, LAMA4, PDE5A
coronary artery disease
4.30E-02 AKAP13, LAMA4, PDE5A
3
vasoconstriction of blood vessel
4.54E-02 PDE5A
1
hypertension
4.55E-02 AKAP13, CDC27, PDE5A
3

Table 8. Calculated p-values of figure 6 data. Only statistically significant p>0.05 values are
included.
4.3.3 Verification of LAMA4 Gene Variant
To verify amino acid conservation among species, protein identification for LAMA4 in
mouse, rat, chick, and zebrafish was retrieved from the UniProt Consortium Protein
Knowledgebase (Jain 2009, Magrane 2011). BLAST alignment with the clustalo algorithm was
conducted with the UniProtKB identifiers for each species: Q16363 (Human), P97927 (Mouse),
Q5SNU9 (Zebrafish), F1NSZ5 (Chick), and F1RZM4 (Pig). The alignment confirmed
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conservation of the expected amino acid in this position further supporting the importance of the
change in amino acid sequence at this position (Figure 7).

Figure 7. BLAST alignment of LAMA4 across species. Aspartic Acid (D) at amino acid 879 is
conserved.
LAMA4 BED file: chr6 112,535,827 112,682,521 was submitted to UCSC liftOver
(Hinrichs et. al. 2006) and the converted start and stop positions of the chromosome were
returned. After translation to the latest build, the nucleotide coordinate 112,463,353 was used as
search criteria to verify no SNP data is associated with this particular variant which would
diminish the novel status. In 2221 NCBI SNPs for the LAMA4 gene there were no matches.
SIFT analysis (Ng 2003) was repeated with the updated coordinates to ensure the novel
and damaging status remained current. Chromosome coordinates 6,112463353,1,C/G were
entered into the submission form. Output options included OMIM Disease and Allele Frequencies
(All HapMap Populations). The SIFT score (0) predicted the amino acid substitution is damaging.
No dbSNP ID, allele frequencies, or OMIM disease associations were reported.
PolyPhen-2 (Polymorphism Phenotyping v2, Adzhubei et. al 2010) analysis was also
repeated to ensure the amino acid change was still considered damaging. A score of 1.0 was
returned confirming the damaging status. The multiple sequence alignment used in the PolyPhen2 pipeline, further confirms sequence conservation at this location (Figure 8).
To further verify novelty of this variant, the Exome Variant Server (EVS) was queried
and the variant was not found. The coordinates were expanded to look in the region flanking the
variant of interest (4,875 alleles with data from this region) and remained novel (October 21,
2011). This analysis was repeated in February 2012, when the data set had been updated to 5400
exomes. There were no occurrences of the LAMA4 D879H variant in 7020 alleles of the
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European cohort. One occurrence of this variant was identified in 1 of 3738 African American
alleles that covered that region. No phenotype or clinical associations, known SNP IDs, or
associated publications were assigned to this variant so it retains its novel and rare status (Exome
Variant Server).

Figure 8. PolyPhen-2 alignment of LAMA4. Results illustrate the conservation of aspartic acid at
position 879.
4.3.4 Laminin Alpha-4 Protein Modeling
The cytosine to guanine nucleotide change results in a change in the amino acid
sequence. The expected triplet GAT encodes a negatively charged aspartic acid (D). The
occurrence of a cytosine in place of the guanine (CAT) encodes for histidine (H), which is a
positively charged amino acid at neutral pH. Designing a homology model would be extremely
interesting to determine if the D to H mutation causes any conformational changes in the protein,
especially since PolyPhen-2 and SIFT analysis predict the variant to be damaging.
No human model of laminin proteins is available. The G1 domain of mouse laminin
alpha-2 is the most homologous to the G1 domain of human laminin alpha-4. The crystal
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structure of the mouse LG1-3 region of the laminin alpha2 chain (PDB ID 2WJS) served as a
backbone for the laminin-4 wild type and mutated models (Carafoli et. al. 2009).
Blastp alignments were conducted to verify the sequence segment to utilize for the model
(Figure 9). The procedure was repeated for the mutated model; aspartic acid was replaced with a
histidine at amino acid 879 (Figure 10). The laminin alpha-4 sequence is based on the Blastp
alignment of amino acids 875-1013 which encode part of the laminin G1 domain. The amino
acids in the pdb file after amino 2324 were deleted to eliminate the G2 and G3 domains in the
2WJS sequence, resulting in a more accurate depiction of the protein and simplifying the view of
the end model. The MODELLER alignment algorithm (Altschul 1990) was used to generate the
final sequence alignment of the human laminin alpha-4 and mouse laminin alpha-2 proteins.

Figure 9.Blastp alignment of human wild type laminin alpha-4 to mouse laminin alpha-2 protein.

Figure 10. Blastp alignment of human mutated (D879H) laminin alpha-4 to mouse laminin alpha2 protein.
Homology modeling did not demonstrate significant structural changes between the wild
type laminin alpha-4 protein and the mutated version (Figure 11). The D879H coding change
occurs in the G1 domain of the protein. In mouse, the laminin alpha-2 LG1 domain is
hypothesized to offer a necessary protein surface for integrin binding. Large surface regions not
blocked by carbohydrate modifications are present in the LG1 domain. The faces of the LG1 β –
sandwich are free of carbohydrates in the alpha chain of mouse (Carafoli et. al. 2009) and the
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virtual human model is expected to be free of carbohydrates as well, therefore capable of binding.
Since this domain is suggested to act as an adhesive factor for endothelial cells (Lian et. al. 2006),
it was proposed that this mutation could disrupt proper cell binding, leading to catastrophic
effects on the base framework of the circulatory system and cardiogenesis. Although the general
structure of the mutated model does not appear to be altered as compared to the wild type model,
it is still formally possible that the cell binding process is disrupted.
The laminin alpha-4 mutation is 40 bases from the proposed binding site amino acids
919-1207 (Gonzales 2002) and points out into solution. Depending on the pH, the histidine will
express a negative or neutral charge. The change from the negative aspartic acid to the neutral or
positive histidine could affect binding or structure. The mutation could lead to the formation of
salt bridges with lysine or histidine or arginine within that sequence, potentially altering the
structure. A change in the charge could remotely affect binding interactions. Without the
availability of a crystal structure it is difficult to ascertain if any of these rearrangements is
actually taking place.

Figure 11. Homology models of laminin alpha-4 protein. (a) wild-type (b)D879H mutation
mapped to the wild-type model (c) overlay of wild-type and mutated models.
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This structural analysis, however, does not invalidate the potential connection that this
variant may have with the HLHS pathway. It is difficult to analyze the impact of the LAMA4
mutation because the crystal structure of the human protein has not been solved. This homology
model serves as a proposal of the protein and does not indicate this specific mutation causes
structural differences between the two models.
4.4. LAMA4 and GJB2 Relationship - Pathway Analysis
GeneMANIA (Warde-Farley et. al. 2010) was employed to examine potential physical
interactions of LAMA4 and GJB2. LAMA4 and GJB2 were queried with GO biological function
based weighting. GeneMANIA provided evidence of physical interactions between the two genes
mediated by DAG1 and CAV1 (Figure 12). DAG1 is a laminin binding component of the
dystrophin-glycoprotein complex (Stelzer et. al. 2012). The interaction of LAMA2 and DAG1
has been well described. Caveolin1 (CAV1) interacts directly with G-protein alpha subunits and
can functionally regulate their activity (Stelzer et. al. 2012). It is highly expressed in the vascular
endothelium and to a lesser extent in cardiac fibroblasts and smooth muscle. CAV1 knockout
mice express cardiac hypertrophy and left ventricular dilation and dysfunction. The heart of
CAV1 knockout mice exhibit evidence for endothelial dysfunction as well (Krieger et. al. 2010).
The LAMA4-DAG1-CAV1-GJB2 physical interaction was heavily weighted based on
the supporting reference data. The interaction between LAMA4 and DAG1 is supported by iRefMINT and iRef - small scale studies sources. The DAG1 CAV1 interaction is supported by
evidence from BioGRID small scale studies and iRef-small scale studies. BioGRID small scale
studies, iRef -HPRD, iRef -OPHID, and iRef - small scale studies provide evidence of the
interaction between CAV1 and GJB2. DAG, CAV1, and GJB2 are involved in cell-cell junction
assembly. LAMA4 and DAG1 interactions are more closely related through ECM and basement
membrane functions. DAG1 and CAV1 interactions involve protein maintenance and cell –cell
junction assembly, as does GJB2.
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Figure 12: Physical interactions of Human LAMA4 and GJB2. GeneMANIA query results. The
queried genes demonstrate direct and indirect physical interactions suggesting they may be
involved in related biological processes. This is further supported by the common functions such
as cell-cell junction organization, cell-cell junction assembly, and maintenance of protein
locations shared by some genes in the network.
LAMA4, GJB2, GJA1, DAG1, and CAV1 were queried under similar conditions to
determine if an obvious relationship was present that could be related associated to HLHS.
Indirect physical interactions were present and well supported (Figure 13). A query for pathway
relationships did not connect all genes involved unless the number of returned genes was
expanded to 100 suggesting a distant relationship or a missing link between the two main groups
and excluding GJB2 (Figure 14).
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Figure 13. GeneMANIA analysis of LAMA4, GJB2, DAG1, CAV1, and GJA1 relationships.
The queried genes demonstrate direct and indirect physical interactions suggesting they may be
involved in related biological processes.

Figure 14. GeneMANIA analysis of GJB2, LAMA4, GJA1, DAG1, and CAV1. Network
analysis shows extending the number of returned genes to 100 does not strongly connect all
queried genes. Based on this analysis it is unlikely that together they are involved in the
development of HLHS.
4.5 LAMA4 and GJB2 Relationship - Family Pedigree
The subject family is comprised of three sons. A history of cardiac anomalies on the
maternal side has been documented. One of the sons does not carry any congenital heart defect
(labeled as ‘unaffected sibling’). One of the sons (labeled as ‘proband’) is affected by a serious
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congenital heart defect known as hypoplastic left heart syndrome (HLHS). A daughter who did
not survive due to a spontaneous abortion (fetal demise) also was affected by HLHS (labeled as
‘fetus’). The DNA of the parents and these offspring were available at the onset of the study.
The DNA of another son became available later in the study. This child is affected with a
longer than normal QT. A deaf phenotype caused by a deletion in the Connexin 26 (GJB2) gene
is also present on the maternal side of the family. This child has a homozygous deletion in this
gene and therefore expresses the deaf phenotype.
Sequencher DNA analysis indicated that both the father and mother are heterozygous for
the deletion. The non-HLHS child is homozygous for the deletion and thereby expresses the deaf
phenotype (Figure 15). The mother and non-HLHS child both are affected by non-HLHS cardiac
abnormalities. It is unknown if the maternal grandmother also expresses a CHD phenotype.
Perhaps some protection is created by the GJB2 deletion leading to less severe forms of CHD,
however further experimentation will need to be conducted to verify this suggestion.

Figure 15. Family pedigree chart. Family members screened for LAMA4 and GJB2 by Sanger
sequencing are indicated by the identification number under the nodes. Proband is indicated by *.
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CHAPTER 5. CONCLUSION AND FUTURE DIRECTIONS
The evidence presented in this thesis suggests the D879H variant in LAMA4 is involved
in the development of HLHS. Mutation predictors SIFT and PolyPhen-2 suggested that the amino
acid change is damaging and novel. The expected amino acid is highly conserved across species
implying that it is important to the function of the protein. Furthermore, all immediate family
members that carry the mutated version of the allele exhibit a form of cardiac abnormalities.
Scientific literature indicates that the protein is expressed in the cardiovascular system
during heart development and in the adult aorta. If HLHS in fact develops as a result of
embryonic alterations in blood flow variations, this could indicate that LAMA4 is a culprit in the
pathology of this syndrome. Losses of integrin binding during embryonic development affecting
the shape of cardiomyocytes and subsequent changes in ventricle morphology would support this
hypothesis due to the implications these changes would have on blood flow. Mouse knockout
studies further support the importance of LAMA4 in the cardiovascular system and heart function
by the appearance of leaky vasculature, premature death due to cardiac dysfunction, and the
changes in cardiomyocytes and incidence of cardiomyopathy.
Homology modeling did not provide strong evidence that this particular mutation is
causative. However, until the human structure is crystallized it is difficult to determine how
accurate the model is. A model including the other LAMA4 non-novel variants found in the
exome sequencing data may provide sufficient evidence to determine the inclusion of all the
variations in this gene lead to an overall conformational change. The proposed structural effect
could cause a disruption in protein binding leading to poor interaction of endothelial cell and
cardiomyocytes with the extracellular matrix which could contribute to cardiomyopathy and
compromised vasculature related to HLHS.
Pathway analysis indicates that LAMA4 interacts with genes such as PRKCA and
AKAP13which have known cardiac associations. Perhaps examining only the variants with
novel, nonsynonymous, and damaging characteristics is too limiting to determine the cause of this
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syndrome. The indirect relationship of LAMA4 and GJA1 is interesting as GJA1 is described in
the arrhythmogenic right ventricular cardiomyopathy pathway (ARVC). The suggested
interaction with DAG1 is also promising as the KEGG database indicates it is involved with
laminin in the Hypertrophic cardiomyopathy (HCM), Dilated cardiomyopathy (DCM), and Viral
myocarditis disease pathways (Kanehisa et. al. 2000, 2012).
The relationship of AKAP13 and LAMA4 also may worthwhile of further exploration.
Perhaps the coupling of mutations in these genes contributes to the development of HLHS. Three
of the four children that carry both the LAMA4 and AKAP13 variants, two are diagnosed with
HLHS, and the other has a longer than normal QT, possibly indicating dominant inheritance of
the variant and reduced penetrance of the phenotype. IPA pathway analysis of the original
variant list indicates that AKAP13 is related to cardiovascular disease and most specifically
cardiac hypertrophy. AKAP13 is involved in a cellular response known as pathological cardiac
hypertrophy. This syndrome includes increased cardiomyocyte size and greater organization of
the sarcomere (Carnegie et. al. 2008). Since cardiomyocytes provide the foundation of
sarcomeres which are responsible for heart contraction, mutations in these genes could affect
blood flow. Interestingly DAG1 and CAV1 are members of subsarcolemmal complexes involved
in contraction through supporting organ architecture, transmitting force between cells, and signal
transduction pathways (Ahmad 2005). PRKCA is also involved in this pathway. GeneMANIA
analysis indicated LAMA4 has a direct pathway connection to both PRKCA and AKAP13.
PRKCA and AKAP13 have a direct physical interaction (Figure 4.) and their functional
biological relationship has been well described (Carnegie et. al. 2004, Ahmad et. al. 2005). If
HLHS is indeed due to an alteration in blood flow during embryogenesis, perhaps the combined
effect of the mutations in these three genes is significant in this patient.
DNA sequencing combined with physical interaction analysis suggests that there may be
an indirect relationship between hearing impairment caused by a deletion in GJB2, the D879H
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mutation in the LAMA4 gene, and CHD. However, since neither of the HLHS children carry the
GJB2 deletion, it is not possible to conclude this relationship is specific to HLHS. Additionally,
the relationship is based on physical evidence that does not necessarily imply that the interactions
are part of a biological pathway of the syndrome. The hypothesis cannot totally be discarded
because even though the proteins are not known to interact at this time does not definitively mean
the interaction is not possible. Research has suggested that there are links between hearing
impairment and cardiac dysfunction, therefore the relationship of GJB2 to HLHS may not have
been uncovered as of yet. Further investigation of these relationships may link these mutations to
the development of CHD or reveal that the GJB2 deletion modulates the severity of CHD. This
hypothesis is corroborated by evidence that the mother and one of the children do not show
HLHS, and they are both positive for the LAMA4 variant and a deleted GJB2 allele.
Additional analysis such as binding and expression assays will be useful to further
determine the involvement of the LAMA4 mutation in regards to HLHS. The inclusion of genes
such as PRKCA, AKAP13, DAG1, GJB2, and CAV1 may result in a more in-depth
understanding of the potential physical or pathway interactions. It also may prove worthwhile to
compare pathway analysis of Osteogenesis Imperfecta (a connective tissue disorder related
collagen, another integral basement membrane protein. Belmont et. al. 2011) with HLHS to
further investigate the relationship between expression of the deaf phenotype and CHD in this
family.
The systematic approach implemented in this study serves as an efficient and effective
guideline to conduct unique variant detection in relationship to disease. Integrating genomic and
proteomic methods along with the application of bioinformatic tools provides ample information
to draw conclusions about the relationships of variants and the syndrome under investigation in
an efficient and effective manner.

43
BIBLIOGRAPHY
Aberdam D, Virolle T, Simon-Assmann P. Transcriptional regulation of laminin gene expression.
Microsc Res Tech. 2000 Nov 1;51(3):228-37. Review. PubMed PMID: 11054873.
Adams, J. DNA sequencing technologies. Nature Education (2008). 1(1)
Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, Kondrashov AS,
Sunyaev SR. A method and server for predicting damaging missense mutations. Nat Methods.
2010 Apr;7(4):248-9. PubMed PMID: 20354512; PubMed Central
Ahmad F, Seidman JG, Seidman CE. The genetic basis for cardiac remodeling. Annu Rev
Genomics Hum Genet. 2005;6:185-216. Review. PubMed PMID: 16124859.
Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. Basic local alignment search tool. J Mol
Biol. 1990 Oct 5;215(3):403-10. PubMed PMID: 2231712.
Barron DJ, Kilby MD, Davies B, Wright JG, Jones TJ, Brawn WJ. Hypoplastic left heart
syndrome. Lancet. 2009 Aug 15;374(9689):551-64. Review. PubMed PMID: 19683641.
Belkin AM, Stepp MA. Integrins as receptors for laminins. Microsc Res Tech. 2000 Nov
1;51(3):280-301. Review. PubMed PMID: 11054877.
Belmont JW, Craigen W, Martinez H, Jefferies JL. Genetic disorders with both hearing loss and
cardiovascular abnormalities. AdvOtorhinolaryngol. 2011;70:66-74. Epub 2011 Feb 24.
Review. PubMed PMID: 21358187.
Bernstein FC, Koetzle TF, Williams GJ, Meyer EF Jr, Brice MD, Rodgers JR, Kennard O,
Shimanouchi T, Tasumi M. The Protein Data Bank: a computer-based archival file for
macromolecular structures. J Mol Biol. 1977 May 25;112(3):535-42. PubMed PMID: 875032.
Borecki IB, Province MA. Genetic and genomic discovery using family studies. Circulation. 2008
Sep 2;118(10):1057-63. Review. PubMed PMID: 18765388.
PDB ID: 2WJS. Carafoli F, Clout NJ, Hohenester E. Crystal structure of the LG1-3 region of the
laminin alpha2 chain. J Biol Chem. 2009 Aug 21;284(34):22786-92. Epub 2009 Jun 24.
PubMed PMID: 19553699; PubMed Central PMCID: PMC2755686.
Carnegie GK, Soughayer J, Smith FD, Pedroja BS, Zhang F, Diviani D, Bristow MR, Kunkel
MT, Newton AC, Langeberg LK, Scott JD. AKAP-Lbc mobilizes a cardiac hypertrophy
signaling pathway. Mol Cell. 2008 Oct 24;32(2):169-79. PubMed PMID: 18951085; PubMed
Central PMCID: PMC3169907.
Chang RK, Gurvitz M, Rodriguez S. Missed diagnosis of critical congenital heart disease. Arch
Pediatr Adolesc Med. 2008 Oct;162(10):969-74. PubMed PMID: 18838650.
Centers for Disease Control and Prevention. Racial Differences by gestational Age in Neonatal
Deaths Attributable to Congenital Heart Defects – United states 2003-2006. MMWR
2007.
59: 1208-1209.

44
National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control
and Prevention March 13, 2012 Pediatric Genetics, Screening for Critical Congenital Heart
Defects Retrieved from:http://www.cdc.gov/ncbddd/pediatricgenetics/pulse.htmlLast
Accessed March 18, 2012
Danes BS, Hodson ME, Batten J. Cystic fibrosis: Evidence for a genetic compound from a family
study in cell culture. Clin Genet. 1977 Feb;11(2):83-90. PubMed PMID: 837566.
Dasgupta C, Martinez AM, Zuppan CW, Shah MM, Bailey LL, Fletcher WH. Identification of
connexin43 (alpha1) gap junction gene mutations in patients with hypoplastic left heart
syndrome by denaturing gradient gel electrophoresis (DGGE). Mutat Res. 2001 Aug 8;479(12):173-86. PubMed PMID: 11470490.
Davies Kevin. Seize the New: Laying the Clinical Genomics Pipeline in Wisconsin. Bio-IT
World. (2011). 10(5):19-20, 22
DeHahn KC, Gonzales M, Gonzalez AM, Hopkinson SB, Chandel NS, Brunelle JK, Jones JC.
The alpha4 laminin subunit regulates endothelial cell survival. Exp Cell Res. 2004 Mar
10;294(1):281-9. PubMed PMID: 14980521.
Draus JM Jr, Hauck MA, Goetsch M, Austin EH 3rd, Tomita-Mitchell A, Mitchell ME.
Investigation of somatic NKX2-5 mutations in congenital heart disease. J Med Genet. 2009
Feb;46(2):115-22. PubMed PMID: 19181906; PubMed Central PMCID: PMC2628540.
Durbeej M. Laminins. Cell Tissue Res. 2010 Jan;339(1):259-68. Epub 2009 Aug 20. Review.
PubMed PMID: 19693542.
Eghtesady P, Brar A, Hall M. Seasonality of hypoplastic left heart syndrome in the United States:
a 10-year time-series analysis. J ThoracCardiovasc Surg. 2011 Feb;141(2):432-8. PubMed
PMID: 20817208.
Elliott DA, Kirk EP, Yeoh T, Chandar S, McKenzie F, Taylor P, Grossfeld P, Fatkin D, Jones O,
Hayes P, Feneley M, Harvey RP. Cardiac homeobox gene NKX2-5 mutations and congenital
heart disease: associations with atrial septal defect and hypoplastic left heart syndrome. J Am
CollCardiol. 2003 Jun 4;41(11):2072-6. PubMed PMID: 12798584.
Exome Variant Server, NHLBI Exome Sequencing Project (ESP), Seattle, WA (URL:
http://evs.gs.washington.edu/EVS/). Accessed February 16, 2012.
Feinstein JA, Benson DW, Dubin AM, Cohen MS, Maxey DM, Mahle WT, Pahl E, Villafañe J,
Bhatt AB, Peng LF, Johnson BA, Marsden AL, Daniels CJ, Rudd NA, Caldarone CA,
Mussatto KA, Morales DL, Ivy DD, Gaynor JW, Tweddell JS, Deal BJ, Furck AK, Rosenthal
GL, Ohye RG, Ghanayem NS, Cheatham JP, Tworetzky W, Martin GR. Hypoplastic left heart
syndrome: current considerations and expectations. J Am CollCardiol. 2012 Jan 3;59(1
Suppl):S1-42. Review. Erratum in: J Am CollCardiol. 2012 Jan 31;59(5):544. PubMed
PMID: 22192720.
Fogoros M.D. Richard N. The Heart's Chambers and Valves. About.com Health's Disease and
Condition Guide. Updated December 01, 2003.
http://biology.about.com/od/anatomy/ss/ventricles.htm Date of last access: March 12,
2012.

45
Frenette PS, Atweh GF. Sickle cell disease: old discoveries, new concepts, and future promise. J
Clin Invest. 2007 Apr;117(4):850-8. Review. PubMed PMID: 17404610; PubMed Central
PMCID: PMC1838946.
Frieser M, Nöckel H, Pausch F, Röder C, Hahn A, Deutzmann R, Sorokin LM. Cloning of the
mouse laminin alpha 4 cDNA. Expression in a subset of endothelium. Eur J Biochem. 1997
Jun 15;246(3):727-35. PubMed PMID: 9219532.
Fuerst FC, Kielhauser SM, Gruber G, Stradner MH, Angerer H, Kremser ML, Setzagel D,
Graninger WB. Matrix Metalloproteinase 3 is regulated by the laminin LAMA4 in
Human
Osteoarthritis. Ann Rheum Dis. 2011. 70(Suppl 2):A1-A94
The Gene Ontology Consortium. "Gene ontology: tool for the unification of biology." Nat. Genet.
May 2000;25(1):25-9.
Gilboa SM, Salemi JL, Nembhard WN, Fixler DE, Correa A. Mortality resulting from congenital
heart disease among children and adults in the United States, 1999 to 2006. Circulation. 2010
Nov 30;122(22):2254-63. Epub 2010 Nov 22. PubMed PMID: 21098447.
Gonzalez AM, Gonzales M, Herron GS, Nagavarapu U, Hopkinson SB, Tsuruta D, Jones JC.
Complex interactions between the laminin alpha 4 subunit and integrins regulate endothelial
cell behavior in vitro and angiogenesis in vivo. ProcNatlAcadSci U S A. 2002 Dec
10;99(25):16075-80. Epub 2002 Nov 26. PubMed PMID: 12454288; PubMed Central
PMCID:PMC138567.
Gottfried I, Landau M, Glaser F, Di WL, Ophir J, Mevorah B, Ben-Tal N, Kelsell DP, Avraham
KB. A mutation in GJB3 is associated with recessive erythrokeratodermiavariabilis (EKV)
and leads to defective trafficking of the connexin 31 protein. Hum Mol Genet. 2002 May
15;11(11):1311-6. PubMed PMID: 12019212.
Grossfeld P, Ye M, Harvey R. Hypoplastic left heart syndrome: new genetic insights. J Am Coll
Cardiol. 2009 Mar 24;53(12):1072-4. PubMed PMID: 19298922.
Grossfeld PD. Hypoplastic left heart syndrome: it is all in the genes. J Am CollCardiol. 2007 Oct
16;50(16):1596-7. Epub 2007 Oct 1. PubMed PMID: 17936160.
Grossfeld PD. The genetics of hypoplastic left heart syndrome. Cardiol Young. 1999
Nov;9(6):627-32. Review. PubMed PMID: 10593278. Cited in PMCRelated citations
Hinrichs AS, Karolchik D, Baertsch R, Barber GP, Bejerano G, Clawson H, Diekhans M, Furey
TS, Harte RA, Hsu F, Hillman-Jackson J, Kuhn RM, Pedersen JS, Pohl A, Raney BJ,
Rosenbloom KR, Siepel A, Smith KE, Sugnet CW, Sultan-Qurraie A, Thomas DJ, Trumbower
H, Weber RJ, Weirauch M, Zweig AS, Haussler D, Kent WJ. The UCSC Genome Browser
Database: update 2006. Nucleic Acids Res. 2006 Jan 1;34(Database issue):D590-8. PubMed
PMID: 16381938; PubMed Central PMCID: PMC1347506.
Hinton RB, Martin LJ, Rame-Gowda S, Tabangin ME, Cripe LH, Benson DW. Hypoplastic left
heart syndrome links to chromosomes 10q and 6q and is genetically related to bicuspid aortic
valve. J Am CollCardiol. 2009 Mar 24;53(12):1065-71. PubMed PMID: 19298921; PubMed
Central PMCID: PMC2703749.

46

Hinton RB Jr, Martin LJ, Tabangin ME, Mazwi ML, Cripe LH, Benson DW. Hypoplastic left
heart syndrome is heritable. J Am CollCardiol. 2007 Oct 16;50(16):1590-5. Epub 2007 Oct 1.
PubMed PMID: 17936159.
Hoffman JI. Incidence of congenital heart disease: I. Postnatal incidence. PediatrCardiol. 1995
May-Jun;16(3):103-13. Review. PubMed PMID: 7617503.
Hoffman JI, Kaplan S. The incidence of congenital heart disease. J Am CollCardiol. 2002 Jun
19;39(12):1890-900. Review. PubMed PMID: 12084585.
Iivanainen A, Sainio K, Sariola H, Tryggvason K. Primary structure and expression of a novel
human laminin alpha 4 chain.FEBS Lett.1995 May29;365(2-3):183-8.PubMedPMID:7781776.
Imbeault S, Gauvin LG, Toeg HD, Pettit A, Sorbara CD, Migahed L, DesRoches R, Menzies AS,
Nishii K, Paul DL, Simon AM, Bennett SA. The extracellular matrix controls gap junction
protein expression and function in postnatal hippocampal neural progenitor cells. BMC
Neurosci. 2009 Feb 24;10:13. PubMed PMID: 19236721; PubMed Central PMCID:
PMC2655299.
Jain E, Bairoch A, Duvaud S, Phan I, Redaschi N, Suzek BE, Martin MJ, McGarvey P, Gasteiger
E. Infrastructure for the life sciences: design and implementation of the UniProt website. BMC
Bioinformatics. 2009 May 8;10:136. PubMed PMID: 19426475; PubMed Central PMCID:
PMC2686714.
Kanehisa, M. and Goto, S.; KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids
Res. 28, 27-30 (2000).
Kanehisa, M., Goto, S., Sato, Y., Furumichi, M., and Tanabe, M.; KEGG for integration and
interpretation of large-scale molecular datasets. Nucleic Acids Res. 40, D109-D114 (2012).
Kemperman MH, Hoefsloot LH, Cremers CW. Hearing loss and connexin 26. J R Soc Med. 2002
Apr;95(4):171-7. Review. PubMed PMID: 11934905; PubMed Central PMCID:PMC1279509.
Kleefstra T, Brunner HG, Amiel J, Oudakker AR, Nillesen WM, Magee A, Geneviève D,
Cormier-Daire V, van Esch H, Fryns JP, Hamel BC, Sistermans EA, de Vries BB, van
Bokhoven H. Loss-of-function mutations in euchromatin histone methyl transferase 1
(EHMT1) cause the 9q34 subtelomeric deletion syndrome. Am J Hum Genet. 2006
Aug;79(2):370-7.Epub 2006 Jun 13. PubMed PMID: 16826528; PubMed Central PMCID:
PMC1559478.
Knapp, AA, Metterville, DR, Kemper, AR, Prosser, L, Perrin, JM. Evidence review: Critical
congenital cyanotic heart disease, Final Draft, September 3, 2010. Prepared for the Maternal
and Child Health Bureau, Health Resources and Services Administration.

47
Knöll R, Postel R, Wang J, Krätzner R, Hennecke G, Vacaru AM, Vakeel P, Schubert C, Murthy
K, Rana BK, Kube D, Knöll G, Schäfer K, Hayashi T, Holm T, Kimura A, Schork N, Toliat
MR, Nürnberg P, Schultheiss HP, Schaper W, Schaper J, Bos E, Den Hertog J, van Eeden FJ,
Peters PJ, Hasenfuss G, Chien KR, Bakkers J. Laminin-alpha4 and integrin-linked kinase
mutations cause human cardiomyopathy via simultaneous defects in cardiomyocytes and
endothelial cells. Circulation. 2007 Jul 31;116(5):515-25. Epub 2007 Jul 23. PubMed PMID:
17646580.
Krieger MH, Di Lorenzo A, Teutsch C, Kauser K, Sessa WC. Telmisartan regresses left
ventricular hypertrophy in caveolin-1-deficient mice. Lab Invest. 2010 Nov;90(11):1573-81.
Epub 2010 Jun 28. PubMed PMID: 20585312; PubMed Central PMCID: PMC3248785.
Ladage D, Tilemann L, Ishikawa K, Correll RN, Kawase Y, Houser SR, Molkentin JD, Hajjar RJ.
Inhibition of PKCα/β with ruboxistaurin antagonizes heart failure in pigs after myocardial
infarction injury. Circ Res. 2011 Dec 9;109(12):1396-400. Epub 2011 Oct 13. PubMed PMID:
21998327; PubMed Central PMCID: PMC3237728.
Lewin MB, McBride KL, Pignatelli R, Fernbach S, Combes A, Menesses A, Lam W, Bezold LI,
Kaplan N, Towbin JA, Belmont JW. Echocardiographic evaluation of asymptomatic
parental
and sibling cardiovascular anomalies associated with congenital left ventricular outflow
tract lesions. Pediatrics. 2004 Sep;114(3):691-6. PubMed PMID: 15342840; PubMed
Central PMCID: PMC1361301.
Lian J, Dai X, Li X, He F. Identification of an active site on the laminin alpha4 chain globular
domain that binds to alphavbeta3 integrin and promotes angiogenesis. Biochem Biophys Res
Commun. 2006 Aug 18;347(1):248-53. Epub 2006 Jun 21. PubMed PMID: 16824487.
Libby RT, Champliaud MF, Claudepierre T, Xu Y, Gibbons EP, Koch M, Burgeson RE, Hunter
DD, Brunken WJ. Laminin expression in adult and developing retinae: evidence of two novel
CNS laminins. J Neurosci. 2000 Sep 1;20(17):6517-28. PubMed PMID: 10964957; PubMed
Central PMCID: PMC2924637.
Lin A, Wang RT, Ahn S, Park CC, Smith DJ. A genome-wide map of human genetic interactions
inferred from radiation hybrid genotypes. Genome Res. 2010 Aug;20(8):1122-32. Epub 2010
May 27. PubMed PMID: 20508145; PubMed Central PMCID: PMC2909575.
Lin P, Mao F, Liu Q, Yang W, Shao C, Yan C, Gong Y. A novel deletion mutation in GJB1
causes X-linked Charcot-Marie-Tooth disease in a Han Chinese family. Muscle Nerve. 2010
Dec;42(6):922-6. PubMed PMID: 21104867.
Liu J, Mayne R. The complete cDNA coding sequence and tissue-specific expression of the
mouse laminin alpha 4 chain. Matrix Biol. 1996 Dec;15(6):433-7. PubMed PMID: 9049981.
Magrane M, Consortium U. UniProt Knowledgebase: a hub of integrated protein data. Database
(Oxford). 2011 Mar 29;2011:bar009. Print 2011. PubMed PMID: 21447597; PubMed Central
PMCID: PMC3070428.
Mammano F. Gap Junctions: Cell-Cell Channels in Animals. In: Madame Curie Bioscience
Database [Internet]. Austin (TX): Landes Bioscience; 2000-.Accessed March 16, 2012.

48
McBride KL, Zender GA, Fitzgerald-Butt SM, Seagraves NJ, Fernbach SD, Zapata G, Lewin M,
Towbin JA, Belmont JW. Association of common variants in ERBB4 with congenital left
ventricular outflow tract obstruction defects. Birth Defects Res A ClinMolTeratol. 2011
Mar;91(3):162-8. doi: 10.1002/bdra.20764. Epub 2011 Feb 2. PubMed PMID: 21290564.
McBride KL, Riley MF, Zender GA, Fitzgerald-Butt SM, Towbin JA, Belmont JW, Cole SE.
NOTCH1 mutations in individuals with left ventricular outflow tract malformationsreduce
ligand-induced signaling. Hum Mol Genet. 2008 Sep 15;17(18):2886-93. Epub 2008 Jun 30.
PubMed PMID: 18593716; PubMed Central PMCID: PMC2722892.
McGowan KA, Marinkovich MP. Laminins and human disease. Microsc Res Tech. 2000 Nov
1;51(3):262-79. Review. PubMed PMID: 11054876.
Messina DN, Speer MC, Pericak-Vance MA, McNally EM. Linkage of familial dilated
cardiomyopathy with conduction defect and muscular dystrophy to chromosome 6q23. Am J
Hum Genet. 1997 Oct;61(4):909-17. PubMed PMID: 9382102; PubMed Central PMCID:
PMC1715999.
Metzker ML. Emerging technologies in DNA sequencing. Genome Res. 2005 Dec;15(12):176776. Review. PubMed PMID: 16339375.
Mossé YP, Laudenslager M, Longo L, Cole KA, Wood A, Attiyeh EF, Laquaglia MJ, Sennett R,
Lynch JE, Perri P, Laureys G, Speleman F, Kim C, Hou C, Hakonarson H, Torkamani A,
Schork NJ, Brodeur GM, Tonini GP, Rappaport E, Devoto M, Maris JM. Identification of
ALKas a major familial neuroblastoma predisposition gene. Nature. 2008 Oct 16;455(7215):
930-5. Epub 2008 Aug 24. PubMed PMID: 18724359; PubMed CentralPMCID:PMC2672043.
Mostafavi S, Ray D, Warde-Farley D, Grouios C, Morris Q. GeneMANIA: a real-time multiple
association network integration algorithm for predicting gene function. Genome Biol. 2008;9
Suppl 1:S4. Epub 2008 Jun 27. PubMed PMID: 18613948; PubMed Central PMCID:
PMC2447538.
Mullin JM, Laughlin KV, Ginanni N, Marano CW, Clarke HM, Peralta Soler A. Increased tight
junction permeability can result from protein kinase C activation/translocation and act as a
tumor promotional event in epithelial cancers. Ann N Y Acad Sci. 2000;915:231-6. Review.
PubMed PMID: 11193580.
Nath AK, Krauthammer M, Li P, Davidov E, Butler LC, Copel J, Katajamaa M, Oresic M,
Buhimschi I, Buhimschi C, Snyder M, Madri JA. Proteomic-based detection of a protein
cluster dysregulated during cardiovascular development identifies biomarkers of congenital
heart defects. PLoS One. 2009;4(1):e4221. Epub 2009 Jan 19. PubMed PMID: 19156209;
PubMed Central PMCID: PMC2626248.
National Institues of Health, Department of Health and Human Servies. July 1, 2011. National
Heart Lung and Blood Institute (NHLBI). What are Congenetial Heart defects? Retrieved
from. http://www.nhlbi.nih.gov/health/health-topics/topics/chd/. Most recently accessed
March 22, 2012
Ng PC, Henikoff S. SIFT: Predicting amino acid changes that affect protein function. Nucleic
Acids Res. 2003 Jul 1;31(13):3812-4. PubMed PMID: 12824425; PubMed Central PMCID:
PMC168916.

49
Punta M, Coggill PC, Eberhardt RY, Mistry J, Tate J, Boursnell C, Pang N, Forslund K, Ceric G,
Clements J, Heger A, Holm L, Sonnhammer EL, Eddy SR, Bateman A, Finn RD. ThePfam
protein families database. Nucleic Acids Res. 2012 Jan;40(Database issue):D290-301.
Epub 2011 Nov 29. PubMed PMID: 22127870; PubMed Central PMCID: PMC3245129.
The PyMOL Molecular Graphics System, Version 0.99 Schrödinger, LLC.
Rajagopal SK, Ma Q, Obler D, Shen J, Manichaikul A, Tomita-Mitchell A, Boardman K, Briggs
C, Garg V, Srivastava D, Goldmuntz E, Broman KW, Benson DW, Smoot LB, Pu WT.
Spectrum of heart disease associated with murine and human GATA4 mutation. J Mol Cell
Cardiol. 2007 Dec;43(6):677-85. Epub 2007 Jun 21. PubMed PMID: 17643447; PubMed
Central PMCID: PMC2573470.
Ramensky V, Bork P, Sunyaev S. Human non-synonymous SNPs: server and survey. Nucleic
Acids Res. 2002 Sep 1;30(17):3894-900. PubMed PMID: 12202775; PubMed Central
PMCID: PMC137415.
Reamon-Buettner SM, Ciribilli Y, Inga A, Borlak J. A loss-of-function mutation in the binding
domain of HAND1 predicts hypoplasia of the human hearts. Hum Mol Genet. 2008 May
15;17(10):1397-405. Epub 2008 Feb 14. PubMed PMID: 18276607.
Richards A, Luccarini C, Pope FM. The structural organisation of LAMA4, the gene encoding
laminin alpha4. Eur J Biochem. 1997 Aug 15;248(1):15-23. PubMed PMID: 9310354.
Ringelmann B, Röder C, Hallmann R, Maley M, Davies M, Grounds M, Sorokin L. Expression
of laminin alpha1, alpha2, alpha4, and alpha5 chains, fibronectin, and tenascin-C in skeletal
muscle of dystrophic 129ReJ dy/dy mice. Exp Cell Res. 1999 Jan 10;246(1):165-82. PubMed
PMID: 9882526.
Roche Applied Science. 2007. Retrieved fromhttp://www.roche-appliedscience.com/publications/multimedia/genome_sequencer/amplicon_07/wbt.htm. The genome
Sequencer introduced by Roche Diagnostics and 454 Life Sciences.Last Accessed March 22,
2012
Rogaev EI, Grigorenko AP, Faskhutdinova G, Kittler EL, Moliaka YK. Genotype analysis
identifies the cause of the "royal disease". Science. 2009 Nov 6;326(5954):817. Epub 2009
Oct 8. PubMed PMID: 19815722.
Šali A. and Blundell T. L.. Comparative protein modeling by satisfaction of spatial restraints. J.
Mol. Biol. 234, 779-815, 199
Sander TL, Klinkner DB, Tomita-Mitchell A, Mitchell ME. Molecular and cellular basis of
congenital heart disease. PediatrClin North Am. 2006 Oct;53(5):989-1009, x. Review.
Erratumin: PediatrClin North Am. 2009 Aug;56(4):xix. PubMed PMID: 17027620.
Scott DL, Salmon M, Morris CJ, Wainwright AC, Walton KW. Laminin and vascular
proliferation in rheumatoid arthritis. Ann Rheum Dis. 1984 Aug;43(4):551-5. PubMed PMID:
6383233; PubMed Central PMCID: PMC1001406.
Shendure J, Ji H. Next-generation DNA sequencing. Nat Biotechnol. 2008 Oct;26(10):1135-45.
PubMed PMID: 18846087.

50
Siffel C, Alverson CJ, Correa A. Analysis of seasonal variation of birth defects in Atlanta. Birth
Defects Res A ClinMolTeratol. 2005 Oct;73(10):655-62. PubMed PMID: 16240376.
Snoeckx RL, Hassan DM, Kamal NM, Van Den Bogaert K, Van Camp G. Mutation analysis of
the GJB2 (connexin 26) gene in Egypt. Hum Mutat. 2005 Jul;26(1):60-1. PubMed PMID:
15954104.
Snoeckx RL, Huygen PL, Feldmann D, Marlin S, Denoyelle F, Waligora J, Mueller-Malesinska
M, Pollak A, Ploski R, Murgia A, Orzan E, Castorina P, Ambrosetti U, NowakowskaSzyrwinska E, Bal J, Wiszniewski W, Janecke AR, Nekahm-Heis D, Seeman P, Bendova O,
Kenna MA, Frangulov A, Rehm HL, Tekin M, Incesulu A, Dahl HH, du Sart D, Jenkins L,
Lucas D, Bitner-Glindzicz M, Avraham KB, Brownstein Z, del Castillo I, Moreno F, Blin N,
Pfister M, Sziklai I, Toth T, Kelley PM, Cohn ES, Van Maldergem L, Hilbert P, Roux AF,
Mondain M, Hoefsloot LH, Cremers CW, Löppönen T, Löppönen H, Parving A, Gronskov K,
Schrijver I, Roberson J, Gualandi F, Martini A, Lina-Granade G, Pallares-Ruiz N, Correia C,
Fialho G, Cryns K, Hilgert N, Van de Heyning P, Nishimura CJ, Smith RJ, Van Camp G.
GJB2 mutations and degree of hearing loss: a multicenter study. Am J Hum Genet. 2005
Dec;77(6):945-57. Epub 2005 Oct 19. PubMed PMID: 16380907; PubMed Central PMCID:
PMC1285178.
Stallmeyer B, Fenge H, Nowak-Göttl U, Schulze-Bahr E. Mutational spectrum in the cardiac
transcription factor gene NKX2.5 (CSX) associated with congenital heart disease. Clin Genet.
2010 Dec;78(6):533-40. doi: 10.1111/j.1399-0004.2010.01422.x. PubMed PMID: 20456451.
Stelzer G, Dalah I, Stein TI, Satanower Y, Rosen N, Nativ N, Oz-Levi D, Olender T, Belinky F,
Bahir I, Krug H, Perco P, Mayer B, Kolker E, Safran M, Lancet D. In-silico human genomics
with GeneCards. Hum Genomics. 2011 Oct;5(6):709-17. PubMed PMID: 22155609.
http://www.genecards.org/cgi-in/carddisp.pl?gene=LAMA4&search=LAMA4 Date Last
Accessed: March 15, 2012.
Stelzer G, Dalah I, Stein TI, Satanower Y, Rosen N, Nativ N, Oz-Levi D, Olender T, Belinky F,
Bahir I, Krug H, Perco P, Mayer B, Kolker E, Safran M, Lancet D. In-silico human genomics
with GeneCards. Hum Genomics. 2011 Oct;5(6):709-17. PubMed PMID: 22155609.
http://www.genecards.org/cgi-bin/carddisp.pl?gene=GJA1 Date Last Accessed: March 15,
2012.
Stelzer G, Dalah I, Stein TI, Satanower Y, Rosen N, Nativ N, Oz-Levi D, Olender T, Belinky F,
Bahir I, Krug H, Perco P, Mayer B, Kolker E, Safran M, Lancet D. In-silico human genomics
with GeneCards. Hum Genomics. 2011 Oct;5(6):709-17. PubMed PMID: 22155609.
http://www.genecards.org/cgi-bin/carddisp.pl?gene=PRKCA&search=prkca Date Last
Accessed: March 15, 2012.
Stelzer G, Dalah I, Stein TI, Satanower Y, Rosen N, Nativ N, Oz-Levi D, Olender T, Belinky F,
Bahir I, Krug H, Perco P, Mayer B, Kolker E, Safran M, Lancet D. In-silico human genomics
with GeneCards. Hum Genomics. 2011 Oct;5(6):709-17. PubMed PMID: 22155609.
http://www.genecards.org/cgi-bin/carddisp.pl?gene=DAG1 Date Last
Accessed: March 15,
2012.

51
Stelzer G, Dalah I, Stein TI, Satanower Y, Rosen N, Nativ N, Oz-Levi D, Olender T, Belinky F,
Bahir I, Krug H, Perco P, Mayer B, Kolker E, Safran M, Lancet D. In-silico human genomics
with GeneCards. Hum Genomics. 2011 Oct;5(6):709-17. PubMed PMID: 22155609.
http://www.genecards.org/cgi-bin/carddisp.pl?gene=CAV1 Date Last
Accessed: March 15,
2012.
Stumper O. Hypoplastic left heart syndrome. Postgrad Med J. 2010 Mar;86(1013):183-8. Review.
PubMed PMID: 20237013.
Suzuki N, Yokoyama F, Nomizu M. Functional sites in the laminin alpha chains. Connect Tissue
Res. 2005;46(3):142-52. Review. PubMed PMID: 16147852.
Tchervenkov CI, Jacobs JP, Weinberg PM, Aiello VD, Béland MJ, Colan SD, Elliott MJ,
Franklin RC, Gaynor JW, Krogmann ON, Kurosawa H, Maruszewski B, Stellin G. The
nomenclature, definition and classification of hypoplastic left heart syndrome. Cardiol Young.
2006 Aug;16(4):339-68. Review. PubMed PMID: 16839428.
Thyboll J, Kortesmaa J, Cao R, Soininen R, Wang L, Iivanainen A, Sorokin L, Risling M, Cao Y,
Tryggvason K. Deletion of the laminin alpha4 chain leads to impaired microvessel maturation.
Mol Cell Biol. 2002 Feb;22(4):1194-202. PubMed PMID: 11809810;
PubMed Central
PMCID: PMC134646.
Tomita-Mitchell A, Mahnke DK, Struble CA, Tuffnell ME, Stamm KD, Hidestrand M, Harris
SE, Goetsch MA, Simpson PM, Bick DP, Broeckel U, Pelech AN, Tweddell JS, Mitchell ME.
Human Gene Copy Number Spectra Analysis in Congenital Heart Malformations. Physiol
Genomics. 2012 Feb 7. [Epub ahead of print] PubMed PMID: 22318994.
Tomita-Mitchell A, Maslen CL, Morris CD, Garg V, Goldmuntz E. GATA4 sequence variants in
patients with congenital heart disease. J Med Genet. 2007 Dec;44(12):779-83. PubMed PMID:
18055909; PubMed Central PMCID: PMC2652815.
Tunggal P, Smyth N, Paulsson M, Ott MC. Laminins: structure and genetic regulation. Microsc
Res Tech. 2000 Nov 1;51(3):214-27. Review. PubMed PMID: 11054872.
Van Agtmael T, Bruckner-Tuderman L. Basement membranes and human disease. Cell Tissue
Res. 2010 Jan;339(1):167-88. Epub 2009 Sep 15. Review. PubMed PMID: 19756754.
VanDeVoorde R, Witte D, Kogan J, Goebel J. Pierson syndrome: a novel cause of congenital
nephrotic syndrome. Pediatrics. 2006 Aug;118(2):e501-5. Epub 2006 Jul 24. PubMed PMID:
16864643.
Vaughan CJ, Basson CT. Molecular determinants of atrial and ventricular septal defects and
patent ductus arteriosus. Am J Med Genet. 2000 Winter;97(4):304-9. Review. PubMed PMID:
11376442.
Wang J, Hoshijima M, Lam J, Zhou Z, Jokiel A, Dalton ND, Hultenby K, Ruiz-Lozano P, Ross J
Jr, Tryggvason K, Chien KR. Cardiomyopathy associated with microcirculation dysfunction in
laminin alpha4 chain-deficient mice. J Biol Chem. 2006 Jan 6;281(1):21320. Epub 2005
Oct 3. PubMed PMID: 16204254.

52
Warde-Farley D, Donaldson SL, Comes O, Zuberi K, Badrawi R, Chao P, Franz M, Grouios C,
Kazi F, Lopes CT, Maitland A, Mostafavi S, Montojo J, Shao Q, Wright G, Bader GD, Morris
Q. The GeneMANIA prediction server: biological network integration for gene prioritization
and predicting gene function. Nucleic Acids Res. 2010 Jul;38(Web Server Issue):W214-20.
PubMed PMID: 20576703; PubMed Central PMCID: PMC2896186.
Wat MJ, Shchelochkov OA, Holder AM, Breman AM, Dagli A, Bacino C, Scaglia F, Zori RT,
Cheung SW, Scott DA, Kang SH. Chromosome 8p23.1 deletions as a cause of complex
congenital heart defects and diaphragmatic hernia. Am J Med Genet A. 2009
Aug;149A(8):1661-77. PubMed PMID: 19606479; PubMed Central PMCID: PMC2765374.
Wolfsberg, T. G. Using the NCBI Map Viewer to Browse Genomic Sequence Data.
Current Protocols in Human Genetics. 2011. 69:18.5.1–18.5.25.
Worthey EA, Mayer AN, Syverson GD, Helbling D, Bonacci BB, Decker B, Serpe JM, Dasu T,
Tschannen MR, Veith RL, Basehore MJ, Broeckel U, Tomita-Mitchell A, Arca MJ, Casper
JT, Margolis DA, Bick DP, Hessner MJ, Routes JM, Verbsky JW, Jacob HJ,
Dimmock DP
Making a definitive diagnosis: successful clinical application of wholeexome sequencing in a
child withintractable inflammatory bowel disease. Genet Med.2011 Mar;13(3):255-62.
PubMed PMID: 21173700.
Xu H, Czerwinski P, Hortmann M, Sohn HY, Förstermann U, Li H. Protein kinase C alpha
promotes angiogenic activity of human endothelial cells via induction of vascular endothelial
growth factor. Cardiovasc Res. 2008 May 1;78(2):349-55. Epub 2007 Dec 4. PubMed PMID:
18056764.
Zhu L, Vranckx R, Khau Van Kien P, Lalande A, Boisset N, Mathieu F, Wegman M, Glancy L,
Gasc JM, Brunotte F, Bruneval P, Wolf JE, Michel JB, Jeunemaitre X. Mutations in myosin
heavy chain 11 cause a syndrome associating thoracic aortic aneurysm/aortic dissection and
patent ductus arteriosus. Nat Genet. 2006 Mar;38(3):343-9. Epub 2006 Jan 29. PubMed
PMID: 16444274.
Xiao Wu, Sharpe K., Tianyi Zhang, Hongyan Chen, Wei Zhu, Li, E., Taghavi S., Van Der Lelie,
D. Comparative genetic pathway analysis using structural equation ModelingComputational
Advances in Bio and Medical Sciences (ICCABS), 2011 IEEE 1st International Conference
OnDigital Object Identifier: 10.1109/ICCABS.2011.5729878Publication Year: 2011
Page(s):190 195

